Acacatm1Dejs/Acacatm1Dejs
Tg(Cd4-cre)1Cwi/?
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * DBA/2
|
increased T cell proliferation |
J:209886
|
Airetm1.1Doi/Airetm1.1Doi
Tg(Ins2-TFRC/OVA)296Wehi/0
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell differentiation |
J:135154
|
|
decreased CD4-positive, alpha-beta T cell number |
J:135154
|
Airetm1Mand/Aire+
Tg(Ins2-TFRC/OVA)296Wehi/0
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell differentiation |
J:135154
|
Airetm1Mmat/Airetm2Mmat
Tg(TcraTcrb)425Cbn/?
involves: BALB/c * C57BL/6 * CBA
|
abnormal thymus morphology |
J:141379
|
|
normal
immune system phenotype |
J:141379
|
B2mtm1Unc/B2mtm1Unc
Tg(TcraAI4)1Dvs/0
Tg(TcrbAI4)1Dvs/0
NOD.Cg-B2mtm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
abnormal CD8-positive, alpha beta T cell morphology |
J:93553
|
|
decreased susceptibility to autoimmune diabetes |
J:93553
|
Bcl6tm1.1Toka/Bcl6+
Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6 * NZB
|
decreased T cell proliferation |
J:174014
|
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
Tg(TcrLCMV)327Sdz/?
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal T cell number |
J:63282
|
|
decreased double-positive T cell number |
J:63282
|
|
decreased T cell proliferation |
J:63282
|
|
decreased thymocyte number |
J:63282
|
|
increased double-negative T cell number |
J:63282
|
Btlatm1Dgra/Btlatm1Dgra
Tg(TcraTcrb)425Cbn/?
involves: C57BL/6
|
abnormal peripheral T cell anergy |
J:147751
|
Btlatm1Dgra/Btlatm1Dgra
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal peripheral T cell anergy |
J:147751
|
Btlatm1Kmm/Btlatm1Kmm
Tg(DO11.10)10Dlo/?
involves: 129S/SvEv * BALB/c * C3H * C57BL/6
|
increased T cell proliferation |
J:84084
|
Camltm1Rjb/Camltm2Rjb
Tg(Lck-cre)1Cwi/0
Tg(TcraTcrb)1100Mjb/0
involves: 129 * C57BL/6 * DBA/2
|
abnormal negative T cell selection |
J:100536
|
|
abnormal positive T cell selection |
J:100536
|
|
decreased thymocyte number |
J:100536
|
Card11tm1.1Litt/Card11tm1.1Litt
Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6
|
abnormal T cell activation |
J:180410
|
Casp3tm1Mak/Casp3tm1Mak
Tg(TcrLCMV)327Sdz/0
B6.Cg-Casp3tm1Mak Tg(TcrLCMV)327Sdz
|
abnormal CD8-positive, alpha beta T cell morphology |
J:97650
|
|
decreased cell proliferation |
J:97650
|
|
decreased physiological sensitivity to xenobiotic |
J:97650
|
Ccr7tm1Rfor/Ccr7tm1Rfor
Tg(DO11.10)10Dlo/?
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal cell migration |
J:123482
|
|
abnormal leukocyte migration |
J:123482
|
|
abnormal regulatory T cell physiology |
J:123482
|
Cd3etm1.1Geno/Cd3etm1.1Geno
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:192604
|
|
abnormal positive T cell selection |
J:192604
|
|
increased DN3 thymocyte number |
J:192604
|
Cd3etm1.1Geno/Cd3etm1.1Geno
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
abnormal CD4-positive T cell differentiation |
J:192604
|
|
abnormal positive T cell selection |
J:192604
|
|
increased DN3 thymocyte number |
J:192604
|
Cd3etm1.1Geno/Cd3etm1.1Geno
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
abnormal positive T cell selection |
J:192604
|
|
abnormal T cell differentiation |
J:192604
|
|
abnormal thymus cell ratio |
J:192604
|
|
decreased double-positive T cell number |
J:192604
|
|
decreased T cell number |
J:192604
|
|
increased DN3 thymocyte number |
J:192604
|
Cd3gtm1.1Cage/Cd3gtm1.1Cage
Tg(TcrLCMV)318Sdz/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
abnormal response to infection |
J:142387
|
|
abnormal T cell physiology |
J:142387
|
|
normal
immune system phenotype |
J:142387
|
Cd4tm1Jrp/Cd4tm1Jrp
Tg(TcrAND)53Hed/0
either: (involves: 129S2/SvPas * C57BL/6 * SJL) or (involves: 129S2/SvPas * C57BL/6 * C57BL/10 * SJL)
|
abnormal T cell number |
J:45168
|
|
thymus hyperplasia |
J:45168
|
Cd4tm1Knw/Cd4tm1Knw
Tg(TcraAI4)1Dvs/0
Tg(TcrbAI4)1Dvs/0
NOD.Cg-Cd4tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
increased susceptibility to autoimmune diabetes |
J:93553
|
Cd5tm1.1Chra/Cd5tm1.1Chra
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: C57BL/6 * FVB/N
|
decreased interferon-gamma secretion |
J:189919
|
|
decreased interleukin-2 secretion |
J:189919
|
|
decreased T cell proliferation |
J:189919
|
|
decreased T helper 1 cell number |
J:189919
|
|
increased interferon-gamma secretion |
J:189919
|
|
increased interleukin-6 secretion |
J:189919
|
|
increased interleukin-17 secretion |
J:189919
|
Cd8atm1Asin/Cd8atm1Asin
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2J
|
abnormal CD8-positive, alpha beta T cell morphology |
J:125259
|
Cd8atm1Asin/Cd8atm1Asin
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N
|
abnormal positive T cell selection |
J:126026
|
|
decreased CD4-positive, alpha-beta T cell number |
J:126026
|
|
increased CD8-positive, alpha-beta T cell number |
J:126026
|
Cd8b1tm1Litt/Cd8b1+
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S4/SvJae * C57BL/6J * DBA/2
|
decreased double-positive T cell number |
J:112551
|
Cd8b1tm1Litt/Cd8b1tm1Litt
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S4/SvJae * C57BL/6J * DBA/2
|
abnormal lymph node cell ratio |
J:112551
|
|
abnormal negative T cell selection |
J:112551
|
|
abnormal positive T cell selection |
J:112551
|
|
decreased CD8-positive, alpha-beta T cell number |
J:112551
|
|
increased CD4-positive, alpha-beta T cell number |
J:112551
|
Cd28tm1Mak/Cd28tm1Mak
Tg(TcrLCMV)327Sdz/0
involves: 129S2/SvPas * C57BL/6 * DBA/2
|
abnormal T cell anergy |
J:123989
|
|
decreased cytotoxic T cell cytolysis |
J:123989
|
|
decreased splenocyte proliferation |
J:123989
|
|
decreased T cell proliferation |
J:123989
|
Cd28tm1Pjl/Cd28tm1Pjl
Tg(DO11.10)10Dlo/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal T cell activation |
J:25536
|
|
abnormal T cell proliferation |
J:25536
|
|
abnormal thymocyte activation |
J:25536
|
|
decreased interleukin-2 secretion |
J:25536
|
Cd84tm1Pls/Cd84tm1Pls
Tg(TcraTcrb)425Cbn/?
B6.Cg-Cd84tm1Pls Tg(TcraTcrb)425Cbn
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:157915
|
Cd226tm1.1Cln/Cd226tm1.1Cln
Tg(TcraTcrb)1100Mjb/0
B6.Cg-Cd226tm1.1Cln Tg(TcraTcrb)1100Mjb
|
abnormal T cell activation |
J:159749
|
|
decreased cytotoxic T cell cytolysis |
J:159749
|
|
decreased interferon-gamma secretion |
J:159749
|
|
decreased T cell proliferation |
J:159749
|
Cd247tm2.1Lov/Cd247tm2.1Lov
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:192915
|
Cd274tm1Shr/Cd274tm1Shr
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
increased susceptibility to autoimmune diabetes |
J:153040
|
Cops5tm1Rpar/Cops5tm1Rpar
Tg(Lck-cre)548Jxm/0
Tg(TcraTcrb)425Cbn/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * SJL
|
decreased thymocyte number |
J:132114
|
Ctcftm2Gal/Ctcftm2Gal
Tg(Lck-cre)1Cwi/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * DBA/2J
|
abnormal T cell differentiation |
J:143271
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143271
|
|
decreased CD8-positive, alpha-beta T cell number |
J:143271
|
|
decreased double-positive T cell number |
J:143271
|
Ctcftm2Gal/Ctcftm2Gal
Tg(Lck-cre)1Cwi/0
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell differentiation |
J:143271
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143271
|
|
decreased double-positive T cell number |
J:143271
|
|
decreased T cell number |
J:143271
|
|
increased double-negative T cell number |
J:143271
|
|
increased single-positive T cell number |
J:143271
|
Ctla4tm1All/Ctla4tm1All
Rag1tm1Mom/Rag1tm1Mom
Tg(TcrAND)53Hed/0
involves: 129S/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal T cell activation |
J:119845
|
|
increased interleukin-4 secretion |
J:119845
|
|
increased T cell proliferation |
J:119845
|
Ctla4tm1All/Ctla4tm1All
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraTcrb)8Rest/0
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:140448
|
|
normal
mortality/aging |
J:140448
|
|
normal
pigmentation phenotype |
J:140448
|
Ctla4tm1All/Ctla4tm1All
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * NOD * SJL
|
abnormal splenocyte physiology |
J:109887
|
|
enlarged spleen |
J:109887
|
|
increased acute inflammation |
J:109887
|
|
insulitis |
J:109887
|
|
normal
mortality/aging |
J:109887
|
Ctla4tm1All/Ctla4tm1All
Tg(TcrAND)53Hed/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
abnormal lymphopoiesis |
J:119845
|
|
abnormal T cell activation |
J:119845
|
|
abnormal T cell subpopulation ratio |
J:119845
|
|
increased CD4-positive, alpha-beta T cell number |
J:119845
|
|
increased CD8-positive, alpha-beta T cell number |
J:119845
|
|
premature death |
J:119845
|
Ctla4tm1All/Ctla4tm1All
Tg(TcraTcrb)8Rest/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
decreased CD8-positive, alpha-beta T cell number |
J:140448
|
|
increased CD4-positive, alpha-beta T cell number |
J:140448
|
|
increased interferon-gamma secretion |
J:140448
|
|
premature death |
J:140448
|
|
variable depigmentation |
J:140448
|
Ctla4tm1Shr/Ctla4tm1Shr
Rag2tm1Fwa/Rag2tm1Fwa
Tg(DO11.10)10Dlo/0
involves: 129S/Sv * BALB/c * C3H * C57BL/6
|
abnormal cytokine secretion |
J:110446
|
|
abnormal T cell physiology |
J:110446
|
|
normal
immune system phenotype |
J:110446
|
Ctla4tm1Shr/Ctla4tm1Shr
Tg(DO11.10)10Dlo/0
involves: 129S4/SvJae * BALB/c * C3H * C57BL/6
|
abnormal T cell physiology |
J:57090
|
|
enlarged lymph nodes |
J:57090
|
|
enlarged spleen |
J:57090
|
|
increased T cell proliferation |
J:57090
|
Dock2tm1Tsas/Dock2tm1Tsas
Tg(Tcra2B4)1Mmd/?
Tg(Tcrb2B4)1Mmd/?
involves: C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:84581
|
|
abnormal T cell physiology |
J:84581
|
|
decreased double-positive T cell number |
J:84581
|
Dock8tm1Ysfk/Dock8tm1Ysfk
Il31tm1.1Ysfk/Il31tm1.1Ysfk
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
Dock8tm1Ysfk/Dock8tm1Ysfk
Osmrtm1Mtan/Osmrtm1Mtan
Tg(TcrAND)53Hed/0
involves: 129S/SvEv * C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
Dock8tm1Ysfk/Dock8tm1Ysfk
Tac2em1Ysfk/Tac2em1Ysfk
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
Dock8tm1Ysfk/Dock8tm1Ysfk
Tac2em2Ysfk/Tac2em2Ysfk
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
integument phenotype |
J:305132
|
Dock8tm1Ysfk/Dock8tm1Ysfk
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
dermatitis |
J:305132
|
|
increased pruritus |
J:305132
|
E2f2tm1Zubi/E2f2tm1Zubi
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J
|
abnormal immune system morphology |
J:76318
|
|
abnormal immune system physiology |
J:76318
|
|
enlarged spleen |
J:76318
|
|
increased CD8-positive, alpha-beta T cell number |
J:76318
|
|
increased inflammatory response |
J:76318
|
|
increased susceptibility to autoimmune disorder |
J:76318
|
|
increased T cell proliferation |
J:76318
|
|
premature death |
J:76318
|
|
thymus hypoplasia |
J:76318
|
Ebi3Gt716Lex/Ebi3Gt716Lex
Tg(DO11.10)10Dlo/0
involves: 129S5/SvEvBrd * BALB/c * C3H * C57BL/6
|
abnormal circulating interleukin level |
J:134148
|
|
abnormal T cell differentiation |
J:134148
|
|
decreased susceptibility to bacterial infection |
J:134148
|
|
increased circulating interleukin-17 level |
J:134148
|
|
increased interleukin-17 secretion |
J:134148
|
Elavl1tm1Dkon/Elavl1tm1Dkon
Tg(Lck-cre)I57Jxm/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
B6.Cg-Elavl1tm1Dkon Tg(Lck-cre)I57Jxm Tg(TcraH-Y,TcrbH-Y)71Vbo
|
abnormal negative T cell selection |
J:148866
|
|
increased thymocyte number |
J:148866
|
Elk4tm1Rtr/Elk4tm1Rtr
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129/Sv * C57BL/6 * DBA/2J
|
abnormal positive T cell selection |
J:88515
|
|
decreased CD8-positive, alpha-beta T cell number |
J:88515
|
Elk4tm1Rtr/Elk4tm1Rtr
Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * C57BL/6
|
abnormal positive T cell selection |
J:88515
|
|
abnormal splenic cell ratio |
J:88515
|
|
decreased CD4-positive, alpha-beta T cell number |
J:88515
|
Elk4tm1Rtr/Elk4tm1Rtr
Tg(TcrLCMV)327Sdz/?
involves: 129/Sv * C57BL/6 * DBA/2
|
abnormal positive T cell selection |
J:88515
|
|
decreased CD8-positive, alpha-beta T cell number |
J:88515
|
Erap1tm1Luc/Erap1tm1Luc
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz
involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2
|
normal
immune system phenotype |
J:122479
|
Ets1tm1Jml/Ets1tm1Jml
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S/SvEv * C57BL/6 * C57BL/6J * DBA/2J
|
decreased CD8-positive, alpha-beta T cell number |
J:125056
|
|
normal
immune system phenotype |
J:125056
|
|
increased double-negative T cell number |
J:125056
|
Faddtm1Wnt/Faddtm1Wnt
Tg(Fadd)33Wnt/0
Tg(Lck-cre)I57Jxm/0
Tg(Tcra2C,Tcrb2C)1Dlo/0
involves: 129S4/SvJae * C57BL/6 * C57L * CBA * ICR * SJL
|
increased double-negative T cell number |
J:69617
|
|
thymus hypoplasia |
J:69617
|
Faslpr/Fas+
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * MRL/Mp
|
liver inflammation |
J:72817
|
|
normal
liver/biliary system phenotype |
J:72817
|
|
normal
mortality/aging |
J:72817
|
Fastm1Vbo/Fastm1Vbo
Tg(Ins2-cre)25Mgn/0
Tg(Ins2-HA)165Bri/0
Tg(Tcra/Tcrb)1Vbo/0
Not Specified
|
increased susceptibility to autoimmune diabetes |
J:85985
|
Fbn1Tsk/Fbn1+
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/10 * DBA/2
|
emphysema |
J:57957
|
|
normal
integument phenotype |
J:57957
|
Fbn1Tsk/Fbn1+
Tg(Tcra2C,Tcrb2C)1Dlo/?
involves: C57BL/10 * DBA/2
|
emphysema |
J:57957
|
|
normal
integument phenotype |
J:57957
|
Foxo1tm1Flv/Foxo1tm1Flv
Rag1tm1Mom/Rag1tm1Mom
Tg(CD2-Il7r)1Asin/?
Tg(Cd4-cre)1Cwi/?
Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2
|
decreased T cell number |
J:147057
|
Foxo1tm1Flv/Foxo1tm1Flv
Rag1tm1Mom/Rag1tm1Mom
Tg(Cd4-cre)1Cwi/?
Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * DBA/2
|
decreased T cell number |
J:147057
|
Foxp3tm1.1Ayr/Y
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraTcrb)425Cbn/0
Not Specified
|
normal
immune system phenotype |
J:97029
|
|
no abnormal phenotype detected |
J:97029
|
Gata3tm1Iho/Gata3tm1Iho
Tg(Cd4-cre)1Cwi/0
Tg(DO11.10)10Dlo/0
involves: BALB/c * C3H * C57BL/6 * DBA/2
|
decreased CD4-positive, alpha-beta T cell number |
J:86996
|
Gata3tm1Iho/Gata3tm1Iho
Tg(DO11.10)10Dlo/0
Tg(Lck-cre)1Cwi/0
involves: BALB/c * C3H * C57BL/6
|
arrested T cell differentiation |
J:86996
|
|
decreased CD4-positive, alpha-beta T cell number |
J:86996
|
|
decreased CD8-positive, alpha-beta T cell number |
J:86996
|
|
decreased double-positive T cell number |
J:86996
|
|
small thymus |
J:86996
|
Gata3tm1Jfz/Gata3tm1Jfz
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-cre)1Cwi/0
Tg(Tcra5CC7,Tcrb5CC7)IWep/0
involves: 129S/SvEv * C57BL/6 * DBA/2
|
abnormal T cell differentiation |
J:141145
|
Gimap5m1Btlr/Gimap5m1Btlr
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6J * DBA/2J
|
decreased CD8-positive, alpha-beta T cell number |
J:160090
|
|
decreased thymocyte number |
J:160090
|
Git2Gt(XG510)Byg/Git2Gt(XG510)Byg
Tg(DO11.10)10Dlo/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:160613
|
Git2Gt(XG510)Byg/Git2Gt(XG510)Byg
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6J * DBA/2J
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:160613
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:160613
|
|
abnormal cell migration |
J:160613
|
|
abnormal positive T cell selection |
J:160613
|
|
decreased CD8-positive, alpha-beta T cell number |
J:160613
|
Git2Gt(XG510)Byg/Git2Gt(XG510)Byg
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:160613
|
Gpr15tm1.1Litt/Gpr15tm1.1Litt
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6
|
abnormal immune system physiology |
J:199126
|
Grb2tm1.1Hua/Grb2tm1.1Hua
Tg(DO11.10)10Dlo/0
Tg(Lck-cre)1Jtak/0
involves: 129 * BALB/c * C3H * C57BL/6
|
abnormal T cell differentiation |
J:161294
|
|
decreased CD4-positive, alpha-beta T cell number |
J:161294
|
Grb2tm1.1Hua/Grb2tm1.1Hua
Tg(Lck-cre)1Jtak/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:161294
|
|
decreased CD4-positive, alpha-beta T cell number |
J:161294
|
|
decreased CD8-positive, alpha-beta T cell number |
J:161294
|
|
increased CD8-positive, alpha-beta T cell number |
J:161294
|
|
increased double-positive T cell number |
J:161294
|
Gt(ROSA)26Sortm1(HA)Libl/Gt(ROSA)26Sortm1(HA)Libl
Mogtm1(cre)Gkl/?
Tg(TcraCl4,TcrbCl4)1Shrm/0
involves: 129/Sv * BALB/c * C57BL/6
|
abnormal oligodendrocyte morphology |
J:137838
|
|
abnormal optic nerve morphology |
J:137838
|
|
brain inflammation |
J:137838
|
|
decreased locomotor activity |
J:137838
|
|
demyelination |
J:137838
|
|
impaired righting response |
J:137838
|
|
optic nerve inflammation |
J:137838
|
|
spinal cord inflammation |
J:137838
|
|
tremors |
J:137838
|
|
weight loss |
J:137838
|
Gt(ROSA)26Sortm2(OVA/EGFP)Dwir/Gt(ROSA)26Sor+
Tg(TcraTcrb)1100Mjb/0
Albtm1(cre/ERT2)Mtz/Alb+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased circulating alanine transaminase level |
J:173806
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
|
enlarged liver |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell derived lymphoma incidence |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased plasmacytoma incidence |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
enlarged spleen |
J:181546
|
|
increased B cell number |
J:181546
|
|
premature death |
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
enlarged liver |
J:181546
|
|
enlarged spleen |
J:181546
|
|
increased B cell derived lymphoma incidence |
J:181546
|
|
increased B cell number |
J:181546
|
|
increased plasmacytoma incidence |
J:181546
|
|
premature death |
J:181546
|
H2-Kbm1/H2-Kbm1
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal positive T cell selection |
J:92867
|
H2-Kbm5/H2-Kbm5
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal positive T cell selection |
J:133645
|
H2-T23tm2Cant/H2-T23tm2Cant
Tg(Tcra2D2,Tcrb2D2)1Kuch/?
involves: 129S6/SvEvTac
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:142087
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:142087
|
H2-T23tm3Cant/H2-T23tm3Cant
Tg(Tcra2D2,Tcrb2D2)1Kuch/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:142087
|
H2-T23tm3Cant/H2-T23tm3Cant
Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:142087
|
H2b/H2b
Itktm1Ljb/Itktm1Ljb
Tg(TcrAND)53Hed/?
involves: C3H/HeJ * C57BL/6 * C57BL/10
|
abnormal positive T cell selection |
J:123795
|
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
H2b/H2b
Nfkbidtm1Clay/Nfkbidtm1Clay
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraN15,TcrbN15)L2Elre/?
involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6
|
abnormal thymocyte activation |
J:132071
|
|
decreased interleukin-2 secretion |
J:132071
|
|
decreased T cell proliferation |
J:132071
|
H2b/H2b
Ptcratm1Vbo/Ptcratm1Vbo
Tcratm1Mom/Tcra/Tcrdtm1.1(Tcra)Rsky
Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
|
decreased thymocyte number |
J:131357
|
H2b/H2b
Ptcratm1Vbo/Ptcratm1Vbo
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
H2b/H2b
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraN15,TcrbN15)L2Elre/?
involves: 129S/SvEv * C57BL/6
|
abnormal cytotoxic T cell physiology |
J:133112
|
|
arrested T cell differentiation |
J:133112
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133112
|
|
increased CD8-positive, alpha-beta T cell number |
J:133112
|
|
increased T cell proliferation |
J:133112
|
H2b/H2b
Tcra/Tcrdtm1.1(Tcra)Rsky/Tcra/Tcrdtm1.1(Tcra)Rsky
Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
H2b/H2b
Tcra/Tcrdtm1.1(Tcra)Rsky/Tcra/Tcrdtm1.1(Tcra)Rsky
Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
H2b/H2b
Tcratm1Mom/Tcra/Tcrdtm1.1(Tcra)Rsky
Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal double-negative T cell morphology |
J:131357
|
|
abnormal double-positive T cell morphology |
J:81564
|
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
|
decreased double-positive T cell number |
J:131357
|
|
decreased thymocyte number |
J:131357
|
H2b/H2d
Tg(TcraTcrb)1100Mjb/?
involves: BALB/c * C57BL/6
|
abnormal negative T cell selection |
J:133645
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133645
|
|
small thymus |
J:133645
|
H2b/H2g7
Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * NOD * SJL
|
abnormal mitral valve morphology |
J:275827
|
|
increased hydroxyproline level |
J:275827
|
|
mitral valve inflammation |
J:275827
|
|
rheumatoid arthritis |
J:36815,
J:275827
|
|
thick mitral valve |
J:275827
|
H2b/H2k
Itktm1Ljb/Itktm1Ljb
Tg(TcrAND)53Hed/?
involves: C3H/HeJ * C57BL/6 * C57BL/10
|
abnormal positive T cell selection |
J:123795
|
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
H2b/H2k
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * C57BL/10Sg * C57BR/c
|
abnormal negative T cell selection |
J:133645
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133645
|
|
small thymus |
J:133645
|
H2b/H2s
Tg(TcraTcrb)1100Mjb/?
involves: A/WySn * C57BL/6 * C57BL/10Sg * Swiss
|
abnormal negative T cell selection |
J:133645
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133645
|
|
small thymus |
J:133645
|
H2d/H2d
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraN15,TcrbN15)L2Elre/?
involves: 129S/SvEv * C57BL/6
|
arrested T cell differentiation |
J:133112
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133112
|
|
decreased CD8-positive, alpha-beta T cell number |
J:133112
|
H2d/H2d
Tcra/Tcrdtm1.1(Tcra)Rsky/Tcra/Tcrdtm1.1(Tcra)Rsky
Tg(Tcrb)93Vbo/0
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
|
decreased thymocyte number |
J:131357
|
H2d/H2d
Tg(TcraP1.5,TcrbP1.5)29Amsv/0
Trap1atm1.1Jvde/Y
involves: 129 * BALB/cJ * C57BL/10 * DBA/2
|
abnormal T cell clonal deletion |
J:180807
|
H2g7/H2g7
Ins2tm1Jja/Ins2tm1Jja
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
increased circulating glucose level |
J:111874
|
|
increased susceptibility to autoimmune diabetes |
J:111874
|
H2g7/H2g7
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
increased susceptibility to autoimmune diabetes |
J:111874
|
|
insulitis |
J:111874
|
H2g7/H2g7
Tg(Ins2-Vtcn1)#Xxz/0
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: C57BL/6 * NOD * SJL
|
decreased interferon-gamma secretion |
J:177612
|
|
decreased interleukin-17 secretion |
J:177612
|
|
decreased regulatory T cell number |
J:177612
|
|
decreased susceptibility to autoimmune diabetes |
J:177612
|
H2g7/H2g7
Tg(TcraAI4)1Dvs/0
Tg(TcrbAI4)1Dvs/0
B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
increased susceptibility to autoimmune diabetes |
J:167508
|
H2g7/H2g7
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
B6.Cg-H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased susceptibility to autoimmune diabetes |
J:86926
|
H2g7/H2g7
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
decreased susceptibility to autoimmune diabetes |
J:111874
|
|
insulitis |
J:111874
|
H2g7/H2q
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
increased susceptibility to autoimmune diabetes |
J:111874
|
H2k/H2k
Tg(TcraTcrbAD10)1Hed/?
involves: C57BL/6 * SJL
|
increased CD4-positive, alpha-beta T cell number |
J:124701
|
H2q/H2q
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
decreased susceptibility to autoimmune diabetes |
J:111874
|
|
normal
digestive/alimentary phenotype |
J:111874
|
H2u/H2u
Tg(TCRA)B1Jg/0
Tg(TCRB)C14Jg/0
B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg
|
abnormal double-negative T cell morphology |
J:92992
|
|
abnormal double-positive T cell morphology |
J:92992
|
|
abnormal thymus cell ratio |
J:92992
|
|
absent gamma-delta T cells |
J:92992
|
|
decreased double-positive T cell number |
J:92992
|
|
increased CD4-positive, alpha-beta T cell number |
J:92992
|
|
increased double-negative T cell number |
J:92992
|
|
increased T cell derived lymphoma incidence |
J:92992
|
H2u/H2u
Tg(TCRA)B1Jg/?
Tg(TCRB)C14Jg/?
involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:92991
|
|
abnormal effector T cell morphology |
J:92991
|
|
decreased CD8-positive, alpha-beta T cell number |
J:92991
|
|
decreased double-positive T cell number |
J:92991
|
|
increased autoantibody level |
J:92991
|
|
increased CD4-positive, alpha-beta T cell number |
J:92991
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:92991
|
|
paralysis |
J:92991
|
H2u/H2u
Tg(TCRB)C14Jg/0
B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRB)C14Jg/J
|
abnormal double-negative T cell morphology |
J:92992
|
|
abnormal double-positive T cell morphology |
J:92992
|
|
absent gamma-delta T cells |
J:92992
|
Havcr2tm1Vlcg/Havcr2tm1Vlcg
Tg(TcraTcrb)1100Mjb/?
B6.Cg-Havcr2tm1Vlcg Tg(TcraTcrb)1100Mjb
|
decreased interferon-gamma secretion |
J:209885
|
|
decreased T cell number |
J:209885
|
Hc0/Hc0
Tg(TcrbBL17)1Lmor/0
involves: DBA/1J * SWR/J
|
decreased susceptibility to induced arthritis |
J:134111
|
Hc1/?
Tg(TcrbBL17)1Lmor/0
involves: DBA/1J * SWR/J
|
increased susceptibility to induced arthritis |
J:134111
|
Hcls1tm1Wtn/Hcls1tm1Wtn
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:28146
|
|
decreased double-positive T cell number |
J:28146
|
Hivep2tm1Sis/Hivep2tm1Sis
Tg(DO11.10)10Dlo/?
involves: BALB/cA * C3H * C57BL/6NCrlj * CBA/JNCrlj
|
abnormal positive T cell selection |
J:96024
|
|
abnormal T-helper 2 cell morphology |
J:96024
|
|
decreased single-positive T cell number |
J:72249
|
Icostm1Flv/Icostm1Flv
Tg(TcraTcrb)425Cbn/0
involves: 129S1/Sv * C57BL/6
|
abnormal cytokine secretion |
J:112600
|
Id2tm1Ago/Id2tm1Ago
Tg(TcraTcrb)1100Mjb/0
B6.Cg-Id2tm1Ago Tg(TcraTcrb)1100Mjb
|
abnormal T cell activation |
J:116119
|
Ido2em1Lamn/Ido2em1Lamn
Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * C57BL/6J * SJL
|
autoimmune arthritis |
J:342726
|
Ido2em2Lamn/Ido2em2Lamn
Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * C57BL/6J * SJL
|
autoimmune arthritis |
J:342726
|
Ifngtm1Ts/Ifngtm1Ts
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
Tg(Cd4-cre)1Cwi/0
involves: 129 * C57BL/6 * DBA/2 * NOD * SJL
|
normal
immune system phenotype |
J:196160
|
|
normal
mortality/aging |
J:196160
|
Igh-Jtm1Aigl/Igh-J+
Mogtm1Dpd/Mogtm1Dpd
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
abnormal nervous system morphology |
J:151335
|
|
abnormal optic nerve morphology |
J:151335
|
|
abnormal spinal cord morphology |
J:151335
|
|
CNS inflammation |
J:151335
|
|
demyelination |
J:151335
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
|
muscle hypertonia |
J:151335
|
|
paralysis |
J:151335
|
Igh-Jtm1Aigl/Igh-J+
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal nervous system morphology |
J:151335
|
|
abnormal optic nerve morphology |
J:151335
|
|
abnormal spinal cord morphology |
J:151335
|
|
CNS inflammation |
J:151335
|
|
demyelination |
J:151335
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
|
muscle hypertonia |
J:151335
|
|
paralysis |
J:151335
|
Igh-Jtm1Aigl/Igh-Jtm1Aigl
Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J
|
increased autoantibody level |
J:149511
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:149511
|
Igh-Jtm1Mcdl/Igh-Jtm1Mcdl
Igk-Jtm1Mcdl/Igk-Jtm1Mcdl
Rag1tm1Mom/Rag1tm1Mom
Tg(DO11.10)10Dlo/?
involves: 129S/Sv * BALB/c * C3H * C57BL/6
|
abnormal spleen germinal center morphology |
J:100072
|
|
abnormal T cell differentiation |
J:100072
|
|
increased IgE level |
J:100072
|
|
increased IgG level |
J:100072
|
Ighmtm1Cgn/Ighmtm1Cgn
Tg(TcraR28,TcrbR28)KRNDim/0
involves: 129S2/SvPas * C57BL/6 * NOD * SJL
|
normal
immune system phenotype |
J:36815
|
Igktm1Dhu/Igktm1Dhu
Tg(H2-Ea-HA)HACIIAjca/0
Tg(Tcra/Tcrb)1Vbo/0
C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo
|
autoimmune arthritis |
J:209872
|
Il2tm1Hor/Il2tm1Hor
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Tcra5CC7,Tcrb5CC7)IWep/0
involves: 129P2/OlaHsd * C57BL/10
|
abnormal T cell number |
J:120176
|
|
increased T-helper 17 cell number |
J:120176
|
Il2tm1Hor/Il2tm1Hor
Tcrbtm1Mom/Tcrbtm1Mom
involves: 129P2/OlaHsd * C57BL/6
|
normal
digestive/alimentary phenotype |
J:135589
|
|
normal
immune system phenotype |
J:135589
|
Il2tm1Hor/Il2tm1Hor
Tg(DO11.10)10Dlo/?
C.Cg-Il2tm1Hor Tg(DO11.10)10Dlo
|
abnormal regulatory T cell physiology |
J:88349
|
|
increased activated T cell number |
J:88349
|
|
increased T cell proliferation |
J:88349
|
|
premature death |
J:88349
|
Il2tm1Hor/Il2tm1Hor
Tg(Pgk1-HA)1.1Vbo/?
Tg(Tcra/Tcrb)1Vbo/?
C.Cg-Il2tm1Hor Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo
|
abnormal regulatory T cell physiology |
J:112603
|
|
decreased regulatory T cell number |
J:112603
|
|
increased regulatory T cell number |
J:112603
|
Il2ratm1Dw/Il2ratm1Dw
Tg(Pgk1-HA)1.1Vbo/?
Tg(Tcra/Tcrb)1Vbo/?
C.Cg-Il2ratm1Dw Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo
|
abnormal regulatory T cell physiology |
J:112603
|
|
decreased regulatory T cell number |
J:112603
|
|
increased regulatory T cell number |
J:112603
|
Il4tm1Cgn/Il4tm1Cgn
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
NOD.Cg-Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased susceptibility to autoimmune diabetes |
J:85924
|
|
insulitis |
J:85924
|
Il6sttm1Thir/Il6sttm1Thir
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129 * C57BL/6 * DBA
|
abnormal negative T cell selection |
J:133059
|
Il13tm1.1Anjm/Il13tm1.1Anjm
Tg(DO11.10)10Dlo/0
involves: 129P2/OlaHsd * BALB/c * C3H * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:91403
|
|
decreased interleukin-13 secretion |
J:91403
|
Il15ratm1.1Nsl/Il15ratm1.1Nsl
Tg(TcrAND)53Hed/?
involves: 129X1/SvJ * C57BL/6 * SJL
|
increased T cell proliferation |
J:92705
|
Itktm1Litt/Itktm1Litt
Tg(DO11.10)10Dlo/0
involves: 129S4/SvJae * BALB/c * C3H * C57BL/6J
|
abnormal T-helper 2 physiology |
J:129883
|
Itktm1Litt/Itktm1Litt
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129S4/SvJae * C57BL/6 * DBA/2J
|
abnormal positive T cell selection |
J:31230
|
|
decreased CD4-positive, alpha-beta T cell number |
J:31230
|
|
increased double-positive T cell number |
J:31230
|
Itktm1Litt/Itktm1Litt
Tg(TcrAND)53Hed/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
abnormal lymphocyte morphology |
J:31230
|
|
decreased CD4-positive, alpha-beta T cell number |
J:31230
|
|
increased double-negative T cell number |
J:31230
|
Itktm1Ljb/Itktm1Ljb
Rag1tm1Mom/Rag1tm1Mom
Tg(Tcra5CC7,Tcrb5CC7)IWep/?
involves: 129 * C57BL/10
|
abnormal CD4-positive T cell differentiation |
J:93606
|
|
decreased interferon-gamma secretion |
J:93606
|
|
decreased interleukin-4 secretion |
J:93606
|
|
decreased interleukin-5 secretion |
J:93606
|
|
decreased interleukin-10 secretion |
J:93606
|
Itktm1Ljb/Itktm1Ljb
Tg(Tcra2B4)1Mmd/?
Tg(Tcrb2B4)1Mmd/?
involves: C3H/HeJ * C57BL/6 * C57BL/10
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
Itktm1Ljb/Itktm1Ljb
Tg(Tcra5CC7,Tcrb5CC7)IWep/?
involves: 129 * C57BL/10
|
decreased CD4-positive, alpha-beta T cell number |
J:123795
|
Itktm1Ljb/Itktm1Ljb
Tg(TcraTcrb)1100Mjb/?
involves: 129 * C57BL/6 * C57BL/10
|
normal
immune system phenotype |
J:113408
|
Ksr1tm1Shaw/Ksr1tm1Shaw
Tg(DO11.10)10Dlo/0
involves: BALB/c * C3H * C57BL/6
|
abnormal CD4-positive T cell differentiation |
J:75739
|
|
decreased interleukin-2 secretion |
J:75739
|
|
decreased T cell proliferation |
J:75739
|
Lattm6.1(HBEGF/EGFP)Mal/?
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)1Pas/?
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal T cell physiology |
J:138401
|
Lcktm1Dbs/Lcktm1Dbs
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C3H * C57BL/6 * DBA/2J
|
abnormal positive T cell selection |
J:114660
|
|
abnormal T cell differentiation |
J:114660
|
|
arrested T cell differentiation |
J:114660
|
Lcktm1Dbs/Lcktm1Dbs
Tg(TcraTcrb)425Cbn/0
involves: C3H * C57BL/6
|
abnormal positive T cell selection |
J:114660
|
|
arrested T cell differentiation |
J:114660
|
Lcktm1Dbs/Lcktm1Dbs
Tg(TcraTcrb)1100Mjb/0
involves: C3H * C57BL/6
|
abnormal positive T cell selection |
J:114660
|
|
decreased T cell proliferation |
J:114660
|
Lcp2tm1.1Wz/Lcp2tm1.1Wz
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:150304
|
Lcp2tm3Gak/Lcp2tm3Gak
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S6/SvEvTac * C57BL/6 * DBA/2J
|
abnormal negative T cell selection |
J:132995
|
|
normal
immune system phenotype |
J:132995
|
|
increased CD8-positive, alpha-beta T cell number |
J:132995
|
|
increased double-positive T cell number |
J:132995
|
Lcp2tm3Gak/Lcp2tm3Gak
Tg(TcrAND)53Hed/?
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:132995
|
|
abnormal thymocyte activation |
J:132995
|
Lcp2tm4Gak/Lcp2tm4Gak
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S6/SvEvTac * C57BL/6 * DBA * FVB/N
|
abnormal negative T cell selection |
J:132995
|
|
increased double-positive T cell number |
J:132995
|
Lcp2tm4Gak/Lcp2tm4Gak
Tg(TcrAND)53Hed/?
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:132995
|
|
abnormal thymocyte activation |
J:132995
|
Lime1tm1.1Mal/Lime1tm1.1Mal
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)1Pas/?
B6.Cg-Rag2tm1Fwa Lime1tm1.1Mal Tg(TcraH-Y,TcrbH-Y)1Pas
|
abnormal CD4-positive T cell differentiation |
J:126321
|
|
increased CD4-positive, alpha-beta T cell number |
J:126321
|
Map2k6tm1Ina/Map2k6tm1Ina
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal thymus cell ratio |
J:100093
|
|
decreased apoptosis |
J:100093
|
Map2k6tm1Ina/Map2k6tm1Ina
Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
decreased apoptosis |
J:100093
|
Mapk1tm1Hed/Mapk1tm1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
Tg(Cd4-cre)1Cwi/0
Tg(TcrAND)53Hed/0
involves: 129/Sv * C57BL/6 * DBA/2 * SJL
|
abnormal positive T cell selection |
J:113280
|
|
abnormal T cell subpopulation ratio |
J:113280
|
Mapk1tm1Hed/Mapk1tm1Hed
Mapk3tm1Gpg/Mapk3tm1Gpg
Tg(TcraTcrb)1100Mjb/0
involves: 129/Sv * C57BL/6
|
decreased thymocyte number |
J:113280
|
Mapk1tm1Hed/Mapk1tm1Hed
Tg(Lck-cre)1Cwi/0
Tg(TcrAND)53Hed/0
involves: C57BL/6 * DBA/2 * SJL
|
abnormal positive T cell selection |
J:113280
|
|
abnormal T cell subpopulation ratio |
J:113280
|
Mapk1tm1Hed/Mapk1tm1Hed
Tg(TcrAND)53Hed/0
involves: C57BL/6 * DBA/2 * SJL
|
abnormal double-positive T cell morphology |
J:113280
|
|
abnormal positive T cell selection |
J:113280
|
Mapk1tm1Hed/Mapk1tm1Hed
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
decreased thymocyte number |
J:113280
|
Mcl1tm1Yen/Mcl1tm1Yen
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal double-positive T cell morphology |
J:146246
|
|
decreased CD8-positive, alpha-beta T cell number |
J:146246
|
Mcl1tm1Yen/Mcl1tm1Yen
Tg(TcraTcrb)425Cbn/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
abnormal double-positive T cell morphology |
J:146246
|
|
decreased CD4-positive, alpha-beta T cell number |
J:146246
|
Mertktm1Gkm/Mertktm1Gkm
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
NOD.Cg-Mertktm1Gkm Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased double-positive T cell number |
J:147153
|
|
increased CD8-positive, alpha-beta T cell number |
J:147153
|
|
increased T cell apoptosis |
J:147153
|
Mogtm1(cre)Gkl/Mogtm1(cre)Gkl
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
C57BL/6-Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
Mogtm1Dpd/Mogtm1Dpd
Rag2tm1Cgn/Rag2tm1Cgn
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas * C57BL/6
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
Mogtm1Dpd/Mogtm1Dpd
Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
SJL.Cg-Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:149511
|
Mogtm1Dpd/Mogtm1Dpd
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas * C57BL/6
|
abnormal nervous system morphology |
J:151335
|
|
abnormal optic nerve morphology |
J:151335
|
|
abnormal spinal cord morphology |
J:151335
|
|
CNS inflammation |
J:151335
|
|
demyelination |
J:151335
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:151335
|
|
muscle hypertonia |
J:151335
|
|
paralysis |
J:151335
|
Myo1gtm1.2Mfk/Myo1gtm1.2Mfk
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * FVB/N * SJL
|
abnormal T cell physiology |
J:212451
|
Ncaph2nes/Ncaph2nes
Tg(TcrHEL3A9)1Mmd/0
C57BL/6-Ncaph2nes Tg(TcrHEL3A9)1Mmd
|
abnormal double-negative T cell morphology |
J:123300
|
|
abnormal thymus cell ratio |
J:123300
|
|
decreased double-positive T cell number |
J:123300
|
Ndfip1Gt(RRD002)Byg/Ndfip1Gt(RRD002)Byg
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * BALB/c * C57BL/6
|
normal
immune system phenotype |
J:205692
|
Nfatc3tm1Glm/Nfatc3tm1Glm
Tg(DO11.10)10Dlo/?
involves: 129S2/SvPas * BALB/c * C3H * C57BL/6
|
decreased double-positive T cell number |
J:50124
|
|
increased double-negative T cell number |
J:50124
|
|
small thymus |
J:50124
|
Notch1tm1Agt/Notch1tm1Agt
Notch2tm3Grid/Notch2tm3Grid
Tg(TcrAND)53Hed/?
involves: 129/Sv * 129S1/Sv * C57BL/6 * SJL
|
abnormal humoral immune response |
J:123631
|
|
abnormal response to infection |
J:123631
|
|
decreased interleukin-4 secretion |
J:123631
|
Nr3c1tm1.1Jda/Nr3c1tm1.1Jda
Rag2tm1.1Cgn/Rag2tm1.1Cgn
Tg(Lck-cre)548Jxm/0
Tg(TcrAND)53Hed/0
B6.Cg-Rag2tm1.1Cgn Nr3c1tm1.1Jda Tg(Lck-cre)548Jxm Tg(TcrAND)53Hed
|
decreased double-positive T cell number |
J:189951
|
Patz1tm1.1Welm/Patz1tm1.1Welm
Tg(TcraTcrb)425Cbn/0
involves: C57BL/6
|
abnormal T cell subpopulation ratio |
J:158947
|
|
decreased CD8-positive, alpha-beta T cell number |
J:158947
|
|
increased CD4-positive, alpha-beta T cell number |
J:158947
|
Patz1tm1.1Welm/Patz1tm1.1Welm
Tg(TcraTcrb)1100Mjb/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T cell subpopulation ratio |
J:158947
|
|
decreased CD8-positive, alpha-beta T cell number |
J:158947
|
|
increased CD4-positive, alpha-beta T cell number |
J:158947
|
Pdcd1tm1.1Shr/Pdcd1tm1.1Shr
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
abnormal immune tolerance |
J:153040
|
|
decreased T cell proliferation |
J:153040
|
|
increased susceptibility to autoimmune diabetes |
J:153040
|
|
increased T cell proliferation |
J:153040
|
|
insulitis |
J:153040
|
|
pancreas inflammation |
J:153040
|
|
vascular inflammation |
J:153040
|
Pdcd1tm1Hon/Pdcd1tm1Hon
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:140751
|
Pdcd1tm1Hon/Pdcd1tm1Hon
Vsirtm1Lex/Vsirtm1Lex
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:222944
|
Pgdtm1.1Pse/Pgdtm1.1Pse
Tg(Cd4-cre)1Cwi/0
Tg(TcraTcrb)8Rest/0
involves: C57BL/6 * DBA/2
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:306553
|
Pgdtm1.1Pse/Pgdtm1.1Pse
Tg(Cd4-cre)1Cwi/0
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * DBA/2
|
abnormal cytotoxic T cell physiology |
J:306553
|
Pigrtm1Ohw/Pigrtm1Ohw
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6J
|
decreased lymphocyte cell number |
J:97824
|
|
normal
immune system phenotype |
J:97824
|
|
increased IgA level |
J:97824
|
Pik3cgtm1Dwu/Pik3cgtm1Dwu
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:131923
|
|
abnormal response to infection |
J:131923
|
|
normal
immune system phenotype |
J:131923
|
Pip5k1ctm1.2Ref/Pip5k1ctm1.2Ref
Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
abnormal T cell physiology |
J:164732
|
|
decreased B cell number |
J:164732
|
|
decreased dendritic cell number |
J:164732
|
|
increased interferon-gamma secretion |
J:164732
|
|
increased interleukin-2 secretion |
J:164732
|
|
increased T cell proliferation |
J:164732
|
Plcg1tm1Gcrp/Plcg1tm1Rwen
Tg(Cd4-cre)1Cwi/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129X1/SvJ * C57BL/6 * DBA/2
|
decreased CD8-positive, alpha-beta T cell number |
J:157757
|
|
decreased double-negative T cell number |
J:157757
|
|
increased CD8-positive, alpha-beta T cell number |
J:157757
|
|
increased double-positive T cell number |
J:157757
|
|
thymus hyperplasia |
J:157757
|
Plxna1tm1Kik/Plxna1tm1Kik
Tg(TcraTcrb)425Cbn/?
involves: BALB/c * C57BL/6
|
decreased T cell proliferation |
J:161856
|
Ppp4ctm1Tht/Ppp4ctm1Tht
Tg(Lck-cre)548Jxm/0
Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6 * CBA
|
abnormal positive T cell selection |
J:117684
|
|
decreased double-positive T cell number |
J:117684
|
|
decreased single-positive T cell number |
J:117684
|
Prkcqtm1Litt/Prkcqtm1Litt
Tg(DO11.10)10Dlo/0
involves: 129 * BALB/c * C3H * C57BL/6
|
decreased T cell apoptosis |
J:141930
|
Prkcqtm1Litt/Prkcqtm1Litt
Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal T cell anergy |
J:123989
|
|
decreased cytotoxic T cell cytolysis |
J:123989
|
|
decreased splenocyte proliferation |
J:123989
|
|
decreased T cell proliferation |
J:123989
|
Prkd2tm1.1Shoy/Prkd2tm1.1Shoy
Prkd3tm1.1Shoy/Prkd3tm1.1Shoy
Tg(Lck-cre)1Jtak/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6 * C57BL/6J * DBA/2J
|
decreased thymocyte number |
J:236298
|
|
increased double-positive T cell number |
J:236298
|
Prkd2tm1.1Shoy/Prkd2tm1.1Shoy
Prkd3tm1.1Shoy/Prkd3tm1.1Shoy
Tg(Lck-cre)1Jtak/0
Tg(TcraTcrb)425Cbn/0
involves: 129 * BALB/c * C57BL/6
|
decreased thymocyte number |
J:236298
|
Prkd2tm1.1Shoy/Prkd2tm1.1Shoy
Prkd3tm1.1Shoy/Prkd3tm1.1Shoy
Tg(Lck-cre)1Jtak/0
Tg(TcraTcrb)1100Mjb/0
involves: 129 * C57BL/6
|
decreased thymocyte number |
J:236298
|
Prkdcscid/Prkdcscid
Tg(TcraAI4)1Dvs/0
Tg(TcrbAI4)1Dvs/0
NOD.Cg-Prkdcscid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
abnormal CD4-positive, alpha beta T cell morphology |
J:93553
|
|
increased susceptibility to autoimmune diabetes |
J:93553
|
Prkdcscid/Prkdcscid
Tg(Tcrb)93Vbo/0
involves: Balb/c * C57BL/Ka * C57BL/Lia * CBA/BrA
|
abnormal CD4-positive, alpha beta T cell morphology |
J:111476
|
|
abnormal CD8-positive, alpha beta T cell morphology |
J:111476
|
|
abnormal double-positive T cell morphology |
J:111476
|
|
abnormal single-positive T cell number |
J:111476
|
|
abnormal T cell differentiation |
J:111476
|
Prkdcscid/Prkdcscid
Tg(TcrLCMV)327Sdz/?
NOD.Cg-Emv30b Prkdcscid Tg(TcrLCMV)327Sdz/DvsJ
|
normal
immune system phenotype |
J:71050
|
Prss16tm1.1Mal/Prss16+
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)1Pas/?
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal positive T cell selection |
J:148034
|
|
decreased CD4-positive, alpha-beta T cell number |
J:148034
|
|
decreased single-positive T cell number |
J:148034
|
|
lymph node hypoplasia |
J:148034
|
Prss16tm1.1Mal/Prss16tm1.1Mal
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)1Pas/?
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal positive T cell selection |
J:148034
|
|
decreased CD4-positive, alpha-beta T cell number |
J:148034
|
|
decreased double-positive T cell number |
J:148034
|
|
decreased single-positive T cell number |
J:148034
|
|
lymph node hypoplasia |
J:148034
|
|
spleen hypoplasia |
J:148034
|
|
thymus hypoplasia |
J:148034
|
Psmb8tm1Hjf/Psmb8tm1Hjf
Tg(TcraTcrb)1100Mjb/?
involves: 129P2/OlaHsd * C57BL/6
|
decreased CD8-positive, alpha-beta T cell number |
J:107657
|
Ptpn22tm1.1Kas/Ptpn22tm1.1Kas
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
normal
immune system phenotype |
J:176519
|
Ptpn22tm1.1Kas/Ptpn22tm1.1Kas
Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
increased CD4-positive, alpha-beta T cell number |
J:176519
|
|
increased T cell proliferation |
J:176519
|
Ptprcltng/Ptprctm1Mak
Tg(TcraTcrb)425Cbn/0
involves: 129/Sv * BALB/c * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:158876
|
|
thymus hypoplasia |
J:158876
|
Ptprctm1Mak/Ptprctm1Mak
Tg(TcraTcrb)425Cbn/0
involves: 129/Sv * BALB/c * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:158876
|
Rac2tm1Mddw/Rac2tm1Mddw
Tg(TcrAND)53Hed/0
involves: 129S/SvEv * C57BL/6 * SJL
|
abnormal T cell activation |
J:119437
|
|
decreased circulating interleukin-2 level |
J:119437
|
|
decreased T cell proliferation |
J:119437
|
Rag1tm1Bal/Rag1tm1Bal
Tg(TcraTcrb)1100Mjb/?
involves: 129S4/SvJae * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:133645
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133645
|
|
increased CD8-positive, alpha-beta T cell number |
J:133645
|
Rag1tm1Bal/Rag1tm1Bal
Vav1tm2Tyb/Vav1tm2Tyb
Tg(TcrAND)53Hed/0
involves: 129S4/SvJae * 129S8/SvEv * C57BL/6 * SJL
|
decreased CD4-positive, alpha-beta T cell number |
J:113270
|
Rag1tm1Mom/Rag1+
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
increased T cell derived lymphoma incidence |
J:47667
|
|
premature death |
J:47667
|
Rag1tm1Mom/Rag1tm1Mom
Slc46a2tm1Moki/Slc46a2+
Tg(TcraB12,TcrbB12)1Rest/0
involves: 129 * C57BL/6
|
arrested T cell differentiation |
J:140121
|
|
decreased double-positive T cell number |
J:140121
|
|
increased T cell apoptosis |
J:140121
|
|
thymus hypoplasia |
J:140121
|
Rag1tm1Mom/Rag1tm1Mom
Tg(LPV-TAg1135)11Tvd/0
Tg(TcrLCMV)327Sdz/0
involves: 129S7/SvEvBrd * C57BL/6 * DBA/2
|
increased T cell derived lymphoma incidence |
J:47667
|
|
premature death |
J:47667
|
Rag1tm1Mom/Rag1tm1Mom
Tg(Tcra,Tcrb)HRCAll/0
B6.Cg-Rag1tm1Mom Tg(Tcra,Tcrb)HRCAll
|
abnormal T cell differentiation |
J:131347
|
|
abnormal T cell subpopulation ratio |
J:131347
|
|
absent CD4-positive, alpha-beta T cells |
J:131347
|
|
increased CD8-positive, alpha-beta T cell number |
J:131347
|
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraAI4)1Dvs/0
Tg(TcrbAI4)1Dvs/0
NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs
|
increased susceptibility to autoimmune diabetes |
J:94192
|
Rag1tm1Mom/Rag1tm1Mom
Tg(TcraBDC12-4.1)10Jos/0
Tg(TcrbBDC12-4.1)82Gse/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD
|
decreased CD4-positive, alpha-beta T cell number |
J:111874
|
|
decreased lymphocyte cell number |
J:111874
|
|
decreased pancreatic beta cell number |
J:111874
|
|
decreased thymus weight |
J:111874
|
|
increased circulating glucose level |
J:111874
|
|
increased double-positive T cell number |
J:111874
|
|
increased susceptibility to autoimmune diabetes |
J:111874
|
Rag1tm1Mom/Rag1tm1Mom
Tyrp1B-w/Tyrp1B-w
X/Tg(Tcra,Tcrb)9Rest
involves: 101/Rl * 129S7/SvEvBrd * C3H/Rl * C57BL/6
|
abnormal tumor susceptibility |
J:138466
|
Rag2tm1Fwa/Rag2tm1Fwa
TcraLn3Jae/Tcra+
TcrbLn3Jae/Tcrb+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
|
abnormal double-negative T cell morphology |
J:143006
|
|
absent gamma-delta T cells |
J:143006
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143006
|
|
increased CD8-positive, alpha-beta T cell number |
J:143006
|
Rag2tm1Fwa/Rag2tm1Fwa
TcrbLn3Jae/Tcrb+
involves: 129S/SvEv * 129S4/SvJae * C57BL/6
|
abnormal double-negative T cell morphology |
J:143006
|
|
absent gamma-delta T cells |
J:143006
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143006
|
|
increased double-positive T cell number |
J:143006
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0
involves: 129S/SvEv * C57BL/6 * Swiss Webster
|
increased gastrointestinal stromal tumor incidence |
J:235890
|
|
increased hepatocellular carcinoma incidence |
J:235890
|
|
increased sarcoma incidence |
J:235890
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(DO11.10)10Dlo/0
involves: 129S/SvEv * BALB/c * C3H * C57BL/6
|
normal
immune system phenotype |
J:110446
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Tcra5CC7,Tcrb5CC7)IWep/?
Themis5AT161/Themis5AT161
involves: 129S/SvEv * C57BL/6
|
arrested T cell differentiation |
J:151076
|
|
increased double-positive T cell number |
J:151076
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0
involves: 129S/SvEv * C57BL/6 * C57BL/6NTac * DBA/2
|
abnormal CD4-positive T cell differentiation |
J:125548
|
|
abnormal positive T cell selection |
J:125548
|
|
decreased CD4-positive, alpha-beta T cell number |
J:125548
|
|
increased double-positive T cell number |
J:125548
|
|
thymus hyperplasia |
J:125548
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraCN.B1,TcrbCN.B1)SM1Jen/0
involves: 129S/SvEv * C57BL/6
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:162539
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S/SvEv * C57BL/6J * DBA/2J
|
abnormal CD8-positive, alpha beta T cell morphology |
J:125259
|
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:125259
|
|
abnormal cytotoxic T cell physiology |
J:66565
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
Themis5AT161/Themis5AT161
involves: 129S/SvEv * C57BL/6 * DBA/2
|
decreased single-positive T cell number |
J:151076
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcraTcrbNY8.3)1Pesa/0
NOD.Cg-Rag2tm1Fwa Tg(TcraTcrbNY8.3)1Pesa
|
increased circulating glucose level |
J:94192
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcrHEL3A9)1Mmd/0
involves: 129S/SvEv * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal double-positive T cell morphology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
abnormal thymus cell ratio |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
Rag2tm1Fwa/Rag2tm1Fwa
Tg(TcrHEL3A9)1Mmd/0
Tg(TLK2mHEL)2Ccg/0
involves: 129S/SvEv * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
|
thyroid gland inflammation |
J:78309
|
Rasgrp1tm1.1Wz/Rasgrp1tm1.1Wz
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6J * DBA/2J
|
decreased single-positive T cell number |
J:225109
|
|
increased double-positive T cell number |
J:225109
|
Rasgrp1tm1.1Wz/Rasgrp1tm1.1Wz
Tg(TcraTcrb)425Cbn/?
involves: C57BL/6 * BALB/c
|
abnormal CD4-positive T cell differentiation |
J:225109
|
Rhohtm1Brak/Rhohtm1Brak
Tg(TcraTcrb)425Cbn/?
involves: 129/Sv * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:143161
|
|
normal
immune system phenotype |
J:143161
|
Rinltm1.1Boun/Rinltm1.1Boun
Tg(TcraTcrb)425Cbn/0
involves: C57BL/6
|
abnormal T follicular helper cell differentiation |
J:346452
|
|
increased CD4-positive, alpha-beta T cell number |
J:346452
|
|
increased T follicular helper cell number |
J:346452
|
Rnf128tm1.1Flv/Rnf128tm1.1Flv
Tg(TcraTcrb)425Cbn/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6
|
abnormal peripheral T cell anergy |
J:153216
|
|
decreased T cell proliferation |
J:153216
|
|
increased circulating interleukin-2 level |
J:153216
|
Rnf128tm1.1Flv/Y
Tg(TcraTcrb)425Cbn/0
involves: 129S6/SvEvTac * BALB/c * C57BL/6
|
abnormal peripheral T cell anergy |
J:153216
|
|
decreased T cell proliferation |
J:153216
|
|
increased circulating interleukin-2 level |
J:153216
|
Rnf128tm1Cdon/Rnf128tm1Cdon
Tg(TcraTcrb)425Cbn/0
involves: 129 * BALB/c * C57BL/6
|
abnormal immune tolerance |
J:160681
|
|
increased interferon-gamma secretion |
J:160681
|
|
increased interleukin-2 secretion |
J:160681
|
|
increased splenocyte proliferation |
J:160681
|
Rr79em2Rtew/Rr79em2Rtew
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6J
|
abnormal T cell activation |
J:332957
|
Rr381em2Kap/Rr381em2Kap
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
normal
hematopoietic system phenotype |
J:333471
|
Rr381em2Kap/Rr381em2Kap
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6
|
normal
hematopoietic system phenotype |
J:333471
|
Serpina3gtm1.1Arp/Serpina3gtm1.1Arp
Tg(TcrLCMV)#Sdz/0
involves: C57BL/6 * DBA/2
|
decreased T cell proliferation |
J:189782
|
Serpinb9tm1Arp/Serpinb9tm1Arp
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6
|
abnormal response to transplant |
J:113349
|
Sh2d1atm1Pls/Sh2d1atm1Pls
Slamf6tm1Pls/Slamf6tm1Pls
Tg(TcraTcrb)1100Mjb/0
involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J
|
normal
immune system phenotype |
J:187431
|
Sh2d1atm1Pls/Sh2d1atm1Pls
Tg(DO11.10)10Dlo/Tg(DO11.10)10Dlo
involves: BALB/c * C3H * C57BL/6
|
abnormal cytokine secretion |
J:90484
|
Sh2d1atm1Pls/Sh2d1atm1Pls
Tg(TcraTcrb)425Cbn/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:157915
|
Sh2d1atm1Pls/Sh2d1atm1Pls
Tg(TcraTcrb)1100Mjb/0
involves: 129S6/SvEvTac * C57BL/6
|
abnormal cytotoxic T cell physiology |
J:187431
|
|
decreased cytotoxic T cell cytolysis |
J:187431
|
|
decreased interferon-gamma secretion |
J:187431
|
Sit1tm1Lsmn/Sit1tm1Lsmn
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal CD8-positive, alpha beta T cell morphology |
J:100408
|
|
abnormal positive T cell selection |
J:100408
|
|
abnormal T cell differentiation |
J:100408
|
Sit1tm1Lsmn/Sit1tm1Lsmn
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6
|
abnormal positive T cell selection |
J:100408
|
|
abnormal T cell selection |
J:100408
|
|
thymus hypoplasia |
J:100408
|
Slatm1Weis/Slatm1Weis
Tg(DO11.10)10Dlo/0
involves: 129 * BALB/c * C3H * C57BL/6
|
abnormal positive T cell selection |
J:71804
|
|
abnormal T cell differentiation |
J:71804
|
Slamf1tm1Cpt/Slamf1tm1Cpt
Tg(DO11.10)10Dlo/Tg(DO11.10)10Dlo
involves: BALB/c * C3H * C57BL/6
|
abnormal cytokine secretion |
J:90484
|
Slamf6tm1Pls/Slamf6tm1Pls
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * C57BL/6J
|
normal
immune system phenotype |
J:187431
|
Stat2tm1Jdf/Stat2tm1Jdf
Tg(DO11.10)10Dlo/0
C.Cg-Stat2tm1Jdf Tg(DO11.10)10Dlo
|
normal
immune system phenotype |
J:95855
|
Tagln2tm1Cdj/Tagln2tm1Cdj
Tg(TcraTcrb)425Cbn/0
involves: 129S4/SvJae * C57BL/6
|
abnormal T cell activation |
J:256656
|
Tagln2tm1Cdj/Tagln2tm1Cdj
Tg(TcraTcrb)1100Mjb/0
involves: 129S4/SvJae * C57BL/6
|
abnormal T cell activation |
J:256656
|
Tapbptm1Luc/Tapbptm1Luc
Tg(TcraTcrb)1100Mjb/?
involves: 129S6/SvEvTac
|
normal
immune system phenotype |
J:64177
|
Tapbptm1Luc/Tapbptm1Luc
Tg(TcraTcrb)1100Mjb/?
involves: 129S6/SvEvTac * C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:64177
|
|
abnormal CD8-positive, alpha beta T cell morphology |
J:64177
|
|
abnormal negative T cell selection |
J:64177
|
|
abnormal positive T cell selection |
J:64177
|
|
normal
immune system phenotype |
J:64177
|
Tcf3tm4Zhu/Tcf3tm4Zhu
Tg(Lck-cre)#Zhu/0
Tg(TcrAND)53Hed/0
involves: 129S4/SvJae * C57BL/6 * SJL
|
normal
immune system phenotype |
J:75746
|
|
normal
neoplasm |
J:75746
|
Tcf12tm2Zhu/Tcf12tm2Zhu
Tg(TcrAND)53Hed/0
involves: C57BL/6 * SJL
|
abnormal CD4-positive, alpha beta T cell morphology |
J:120411
|
|
abnormal T cell subpopulation ratio |
J:120411
|
|
arrested T cell differentiation |
J:120411
|
|
increased T cell number |
J:120411
|
Tcra-Jtm1Kgwa/Tcra-Jtm1Kgwa
Tg(Tcrb2B4)1Mmd/0
involves: 129P2/OlaHsd * C3H/HeJ * C57BL/6J
|
abnormal T cell differentiation |
J:50143
|
|
increased double-positive T cell number |
J:50143
|
TcraLn1Ogu/Tcra+
TcrbLn1Ogu/Tcrb+
involves: 129/Sv * C57BL/6
|
abnormal T cell morphology |
J:152069
|
|
increased body weight |
J:152069
|
TcraLn2Ogu/Tcra+
TcrbLn2Ogu/Tcrb+
involves: 129/Sv * C57BL/6
|
abnormal T cell morphology |
J:152069
|
|
increased body weight |
J:152069
|
TcraLn3Jae/Tcra+
TcrbLn3Jae/Tcrb+
B6.Cg-TcrbLn3Jae TcraLn3Jae
|
abnormal double-negative T cell morphology |
J:143006
|
|
abnormal T cell differentiation |
J:143006
|
|
absent gamma-delta T cells |
J:143006
|
|
decreased CD4-positive, alpha-beta T cell number |
J:143006
|
|
decreased double-positive T cell number |
J:143006
|
|
increased CD8-positive, alpha-beta T cell number |
J:143006
|
|
thymus hypoplasia |
J:143006
|
Tcratm1Mom/Tcra/Tcrdtm1.1(Tcra)Rsky
H2b/H2b
Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal double-negative T cell morphology |
J:131357
|
|
abnormal double-positive T cell morphology |
J:81564
|
|
abnormal negative T cell selection |
J:81564
|
|
abnormal T cell differentiation |
J:81564
|
|
decreased double-positive T cell number |
J:131357
|
|
decreased thymocyte number |
J:131357
|
Tcratm1Mom/Tcra/Tcrdtm1.1(Tcra)Rsky
H2d/H2d
Ptcratm1Vbo/Ptcratm1Vbo
Tg(Tcrb)93Vbo/?
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal T cell differentiation |
J:131357
|
|
decreased thymocyte number |
J:131357
|
Tcratm1Mom/Tcratm1Mom
Tcrbtm1Mom/Tcrbtm1Mom
involves: 129 * BALB/c * C57BL/6
|
arrested T cell differentiation |
J:3206
|
|
decreased double-positive T cell number |
J:3206
|
|
thymus hypoplasia |
J:3206
|
Tcrbtm1(Tcrb)Chb/Tcrbtm1(Tcrb)Chb
Not Specified
|
abnormal double-negative T cell morphology |
J:147947
|
|
abnormal T cell morphology |
J:147947
|
|
decreased CD8-positive, alpha-beta T cell number |
J:147947
|
|
increased single-positive T cell number |
J:147947
|
Tcrbtm1(Tcrb)Chb/Tcrbtm1Slek
Not Specified
|
abnormal double-negative T cell morphology |
J:147947
|
|
abnormal T cell morphology |
J:147947
|
|
abnormal T cell receptor beta chain V(D)J recombination |
J:147947
|
|
decreased CD8-positive, alpha-beta T cell number |
J:147947
|
|
increased single-positive T cell number |
J:147947
|
Tcrbtm1(Tcrb)Fwa/Tcrbtm1(Tcrb)Fwa
involves: 129
|
abnormal T cell receptor beta chain V(D)J recombination |
J:131995
|
Tcrbtm1Mom/Tcrb+
Tg(SOD1*G93A)1Gur/0
B6.Cg-Tcrbtm1Mom Tg(SOD1*G93A)1Gur/J
|
abnormal microglial cell physiology |
J:143173
|
|
motor neuron degeneration |
J:143173
|
|
premature death |
J:143173
|
|
weight loss |
J:143173
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J
|
abnormal respiratory system physiology |
J:125656
|
|
abnormal transitional stage B cell morphology |
J:187766
|
|
decreased autoantibody level |
J:187766
|
|
decreased IgE level |
J:125656
|
|
decreased IgG1 level |
J:125656
|
|
decreased IgG level |
J:125656,
J:187766
|
|
decreased plasma cell number |
J:187766
|
|
decreased T cell number |
J:187766
|
|
increased B cell number |
J:187766
|
|
increased follicular B cell number |
J:187766
|
|
increased IgM level |
J:187766
|
|
increased immature B cell number |
J:187766
|
|
increased marginal zone B cell number |
J:187766
|
|
increased mature B cell number |
J:187766
|
|
increased transitional stage T2 B cell number |
J:187766
|
|
increased transitional stage T3 B cell number |
J:187766
|
|
renal glomerular immunoglobulin deposits |
J:187766
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
FVB.129P2-Tcrbtm1Mom Tcrdtm1Mom
|
normal
immune system phenotype |
J:75915
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
involves: 129 * BALB/c * C57BL/6
|
absent CD4-positive, alpha-beta T cells |
J:3206
|
|
absent CD8-positive, alpha-beta T cells |
J:3206
|
|
arrested T cell differentiation |
J:3206
|
|
colitis |
J:15221
|
|
decreased double-positive T cell number |
J:3206
|
|
thymus hypoplasia |
J:3206
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
involves: 129P2/OlaHsd
|
decreased IgA level |
J:97824
|
|
decreased lymphocyte cell number |
J:97824
|
|
normal
immune system phenotype |
J:97824
|
|
increased T cell number |
J:97824
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
involves: 129P2/OlaHsd * C57BL/6
|
abnormal respiratory system morphology |
J:119344
|
|
abnormal respiratory system physiology |
J:119344
|
|
abnormal response to infection |
J:119344
|
|
decreased IgG level |
J:119344
|
|
normal
immune system phenotype |
J:126867
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
B6.129P2-Tcrbtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg Tcrdtm1Mom
|
increased anti-double stranded DNA antibody level |
J:142389
|
|
increased marginal zone B cell number |
J:142389
|
|
spleen hypoplasia |
J:142389
|
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
B6.129-Tcrbtm1Mom Traf3ip2tm1.1Lix Tcrdtm1Mom
|
abnormal glomerular capillary morphology |
J:187766
|
|
abnormal transitional stage B cell morphology |
J:187766
|
|
decreased IgG level |
J:187766
|
|
decreased T cell number |
J:187766
|
|
normal
immune system phenotype |
J:187766
|
|
increased anti-chromatin antibody level |
J:187766
|
|
increased anti-double stranded DNA antibody level |
J:187766
|
|
increased anti-histone antibody level |
J:187766
|
|
increased autoantibody level |
J:187766
|
|
increased IgM level |
J:187766
|
|
increased immature B cell number |
J:187766
|
|
increased marginal zone B cell number |
J:187766
|
|
increased mesangial cell number |
J:187766
|
|
renal glomerular immunoglobulin deposits |
J:187766
|
Tcrbtm1Mom/Tcrbtm1Mom
Tg(H2-K-Cd86)7All/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
abnormal B cell differentiation |
J:112475
|
|
abnormal B cell morphology |
J:112475
|
|
decreased B cell number |
J:112475
|
|
normal
hematopoietic system phenotype |
J:112475
|
Tcrbtm1Mom/Tcrbtm1Mom
Tg(H2-K-Cd86)27All/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
normal
hematopoietic system phenotype |
J:112475
|
Tcrbtm1Mom/Tcrbtm1Mom
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
involves: 129P2/OlaHsd * C3H * C57BL/6 * FVB/N
|
abnormal dermal layer morphology |
J:100506
|
|
decreased IgE level |
J:100506
|
|
skin inflammation |
J:100506
|
|
thick epidermis |
J:100506
|
Tcrbtm2Slek/Tcrbtm2Slek
Trbv13-2tm1(CD2)Zhu/Trbv13-2tm1(CD2)Zhu
involves: 129 * C57BL/6
|
abnormal T cell differentiation |
J:121608
|
Tespa1tm1Smoc/Tespa1tm1Smoc
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129 * C57BL/6 * DBA/2J
|
decreased CD8-positive, alpha-beta T cell number |
J:186446
|
Tespa1tm1Smoc/Tespa1tm1Smoc
Tg(TcraTcrb)425Cbn/0
B6.Cg-Tespa1tm1Smoc Tg(TcraTcrb)425Cbn
|
abnormal T cell differentiation |
J:186446
|
|
decreased CD4-positive, alpha-beta T cell number |
J:186446
|
|
decreased CD8-positive, alpha-beta T cell number |
J:186446
|
Tespa1tm1Smoc/Tespa1tm1Smoc
Tg(TcraTcrb)1100Mjb/0
B6.Cg-Tespa1tm1Smoc Tg(TcraTcrb)1100Mjb
|
abnormal T cell differentiation |
J:186446
|
|
decreased CD4-positive, alpha-beta T cell number |
J:186446
|
|
decreased CD8-positive, alpha-beta T cell number |
J:186446
|
Tg(Alb1-GP33/H2-Kb)1Hpi/0
Tg(Alb1-HBV)66Bri/0
Tg(TcrLCMV)318Sdz/0
involves: C57BL/6 * C57BL/10 * DBA/2
|
liver inflammation |
J:162605
|
Tg(Alb1-GP33/H2-Kb)1Hpi/0
Tg(TcrLCMV)318Sdz/0
involves: C57BL/6 * DBA/2
|
decreased CD8-positive, alpha-beta T cell number |
J:162605
|
Tg(CD2-Ceacam1*4L)1Rsb/0
Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:116136
|
Tg(CD2-Mir181d)38Oers/0
Tg(TcraTcrb)425Cbn/0
involves: C3H * C57BL/6
|
decreased T cell number |
J:212571
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/?
involves: 129S1/Sv * 129X1/SvJ * C57BL/10 * FVB/N
|
abnormal positive T cell selection |
J:126026
|
|
decreased CD4-positive, alpha-beta T cell number |
J:126026
|
|
increased CD8-positive, alpha-beta T cell number |
J:126026
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
involves: BALB/c * C57BL/10
|
decreased CD8-positive, alpha-beta T cell number |
J:113713
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
involves: C57BL/10
|
abnormal positive T cell selection |
J:113713
|
|
increased CD8-positive, alpha-beta T cell number |
J:113713
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
involves: C57BL/10 * CBA/Ca
|
decreased CD8-positive, alpha-beta T cell number |
J:113713
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
involves: C57BL/6 * C57BL/10
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
|
enlarged lymph nodes |
J:217939
|
|
increased T cell number |
J:217939
|
Tg(CD2-TcraF5,CD2-TcrbF5)1Kio/0
Tg(LCKprBCL2)36Sjk/0
involves: C57BL/6 * C57BL/10
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
Tg(CD2-Zbtb7b)C8Rbo/?
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * DBA/2J
|
abnormal T cell differentiation |
J:97610
|
Tg(CD2-Zbtb7b)C8Rbo/?
Tg(TcrLCMV)327Sdz/?
involves: C57BL/6 * DBA/2J
|
abnormal T cell differentiation |
J:97610
|
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
Tg(Cd4-cre)1Cwi/?
Tg(TcraTcrb)425Cbn/?
Traf6tm2Ywc/Traf6tm2Ywc
involves: C57BL/6 * DBA/2
|
abnormal lymphocyte anergy |
J:130882
|
|
increased interleukin-2 secretion |
J:130882
|
Tg(Cd4-NPM/ALK)N1Ingh/0
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * Swiss Webster
|
abnormal double-negative T cell morphology |
J:235890
|
|
abnormal thymus morphology |
J:235890
|
|
increased gastrointestinal stromal tumor incidence |
J:235890
|
|
increased hepatocellular carcinoma incidence |
J:235890
|
|
increased sarcoma incidence |
J:235890
|
|
increased T cell derived lymphoma incidence |
J:235890
|
|
premature death |
J:235890
|
Tg(Cd8aCd8b)3Erob/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * DBA/2
|
abnormal CD4-positive, alpha beta T cell morphology |
J:93004
|
|
abnormal CD8-positive, alpha-beta T cell differentiation |
J:93004
|
|
increased CD8-positive, alpha-beta T cell number |
J:93004
|
Tg(CMV-TcrAHIII12.2)1Ecol/0
C57BL/6-Tg(CMV-TcrAHIII12.2)1Ecol
|
no abnormal phenotype detected |
J:94077
|
Tg(CMV-TcrAHIII12.2)1Ecol/Tg(CMV-TcrAHIII12.2)1Ecol
C57BL/6-Tg(CMV-TcrAHIII12.2)1Ecol
|
no abnormal phenotype detected |
J:94077
|
Tg(DO11.10)10Dlo/?
involves: BALB/c * C3H * C57BL/6
|
abnormal thymus physiology |
J:70572
|
|
decreased CD4-positive, alpha-beta T cell number |
J:70572
|
|
decreased double-positive T cell number |
J:70572
|
Tg(DO11.10)10Dlo/0
Crlf2tm1Wjl/Crlf2tm1Wjl
involves: 129 * BALB/c * C3H * C57BL/6
|
decreased inflammatory response |
J:107431
|
Tg(DO11.10)10Dlo/?
Toxtm1.1Kay/Toxtm1.1Kay
involves: 129S/Sv * BALB/c * C3H * C57BL/6
|
arrested T cell differentiation |
J:131287
|
|
decreased T cell number |
J:131287
|
Tg(H2-Ea-HA)HACIIAjca/0
Tg(Tcra/Tcrb)1Vbo/0
C.Cg-Tg(H2-Ea-HA)HACIIAjca Tg(Tcra/Tcrb)1Vbo
|
abnormal articular cartilage morphology |
J:209872
|
|
abnormal CD4-positive, alpha beta T cell morphology |
J:209872
|
|
abnormal circulating cytokine level |
J:209872
|
|
abnormal lung morphology |
J:209872
|
|
autoimmune arthritis |
J:209872
|
|
heart inflammation |
J:209872
|
|
increased circulating interleukin-6 level |
J:209872
|
|
increased IgG level |
J:209872
|
|
joint inflammation |
J:209872
|
|
kidney inflammation |
J:209872
|
Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
SJL.FVB-Tg(H2-Kb-Tcra,-Tcrb)1640Kurs
|
abnormal cytokine level |
J:149511
|
|
ataxia |
J:149511
|
|
brain inflammation |
J:149511
|
|
CNS inflammation |
J:149511
|
|
demyelination |
J:149511
|
|
increased autoantibody level |
J:149511
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:149511
|
|
increased T-helper 1 cell number |
J:149511
|
|
increased T-helper 17 cell number |
J:149511
|
|
limb paralysis |
J:149511
|
Tg(H2KePCC)2403Stoe/?
Tg(TcraTcrbAD10)1Hed/?
involves: C57BL/6 * SJL
|
abnormal immune tolerance |
J:92997
|
|
abnormal T cell anergy |
J:92997
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92997
|
Tg(H2KmPCC)2939Stoe/0
Tg(Tcra2B4)1Mmd/0
Tg(Tcrb2B4)1Mmd/0
involves: C3H/HeJ * C57BL/6 * SJL
|
abnormal T cell differentiation |
J:50143
|
|
decreased T cell proliferation |
J:50143
|
|
decreased thymocyte number |
J:50143
|
Tg(H2KmPCC)2939Stoe/?
Tg(TcrAND)53Hed/?
involves: C57BL/6 * SJL
|
abnormal immune tolerance |
J:92997
|
|
abnormal T cell anergy |
J:92997
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92997
|
Tg(H2KmPCC)2939Stoe/?
Tg(TcraTcrbAD10)1Hed/?
involves: C57BL/6 * SJL
|
abnormal immune tolerance |
J:92997
|
|
abnormal T cell anergy |
J:92997
|
|
decreased CD4-positive, alpha-beta T cell number |
J:92997
|
Tg(Igk-Eik-H2-Ead)1Flv/0
Tg(Tcra1H3.1,Tcrb1H3.1)1Vire/0
involves: C57BL/6 * SJL
|
decreased double-positive T cell number |
J:124574
|
|
thymus hypoplasia |
J:124574
|
Tg(ILK3mHEL)3Ccg/0
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6JSfd * C57BL/10Sg * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
insulitis |
J:78309
|
Tg(Ins1-Cd80)378Psoh/0
Tg(Ins2-GP)#Psoh/0
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2 * FVB/N
|
absent pancreatic beta cells |
J:209714
|
|
cachexia |
J:209714
|
|
hyperglycemia |
J:209714
|
|
insulitis |
J:209714
|
|
ketosis |
J:209714
|
|
periinsulitis |
J:209714
|
|
premature death |
J:209714
|
Tg(Ins1-Cd80)378Psoh/0
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2 * FVB/N
|
normal
homeostasis/metabolism phenotype |
J:209714
|
Tg(Ins2-GP)#Psoh/0
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2
|
abnormal B cell selection |
J:81285
|
|
normal
homeostasis/metabolism phenotype |
J:209714
|
|
hyperglycemia |
J:81285
|
|
increased urine glucose level |
J:81285
|
Tg(Ins2-HA)165Bri/?
Tg(TcraCl4,TcrbCl4)1Shrm/?
involves: BALB/c * C57BL/6 * C57BL/10
|
hyperglycemia |
J:99756
|
|
insulitis |
J:99756
|
|
postnatal lethality, complete penetrance |
J:99756
|
Tg(Ins2-HA)165Bri/0
Tg(TcraCl4,TcrbCl4)1Shrm/0
involves: BALB/c * C57BL/6 * C57BL/10 * DBA/2
|
abnormal pancreatic islet morphology |
J:99756
|
|
hyperglycemia |
J:99756
|
|
insulitis |
J:99756
|
|
postnatal lethality |
J:99756
|
Tg(Ins2-OVA)307Wehi/0
Tg(TcraTcrb)1100Mjb/0
involves: C57BL/6 * C57BL/6JWehi
|
autoimmune response |
J:99451
|
|
decreased pancreatic beta cell number |
J:99451
|
|
increased urine glucose level |
J:99451
|
Tg(Ins2-TFRC/OVA)296Wehi/0
Tg(TcraTcrb)425Cbn/0
involves: 129P2/OlaHsd * C57BL/6
|
decreased CD4-positive, alpha-beta T cell number |
J:135154
|
|
increased double-positive T cell number |
J:135154
|
Tg(KLK4mHEL)6Ccg/0
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
Tg(Lck-CrmA)1Hed/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
BALB/c * C57BL/6
|
normal
immune system phenotype |
J:100451
|
Tg(Lck-FADD)1Hed/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: BALB/c * C57BL/6J * C57L/J * DBA/2J
|
normal
immune system phenotype |
J:100451
|
Tg(LCK-NFKBIA)5Dwb/?
Tg(Tcra,Tcrb)1Mcd/?
involves: BALB/c * C57BL/6 * DBA/2
|
decreased interferon-gamma secretion |
J:145531
|
Tg(Lck-Stk17b)26.1Wals/?
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * C57BL/10
|
abnormal T cell differentiation |
J:149973
|
|
decreased CD8-positive, alpha-beta T cell number |
J:149973
|
|
decreased thymocyte number |
J:149973
|
|
increased CD8-positive, alpha-beta T cell number |
J:149973
|
Tg(LCKprBCL2)36Sjk/0
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: C57BL/6 * C57BL/6J * DBA/2J
|
abnormal T cell clonal deletion |
J:217939
|
|
decreased thymocyte apoptosis |
J:217939
|
Tg(ML5sHEL)5Ccg/0
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
Tg(ML5sHEL)5Ccg/0
Tg(TcrHEL3A9)1Mmd/0
Tg(TLK2mHEL)2Ccg/0
involves: C57BL/6JSfd * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
|
thyroid gland inflammation |
J:78309
|
Tg(Pgk1-HA)1.1Vbo/?
Tg(Tcra/Tcrb)1Vbo/?
C.Cg-Tg(Pgk1-HA)1.1Vbo Tg(Tcra/Tcrb)1Vbo
|
abnormal regulatory T cell physiology |
J:112603
|
|
increased regulatory T cell number |
J:112603
|
Tg(Pgk1-HA)1.1Vbo/?
Tg(Tcra/Tcrb)1Vbo/?
involves: 129 * BALB/c * C57BL/6J * DBA/2J
|
decreased CD4-positive, alpha-beta T cell number |
J:125750
|
|
increased double-positive T cell number |
J:125750
|
|
increased regulatory T cell number |
J:125750
|
Tg(Tcra2C,Tcrb2C)1Dlo/?
involves: C57BL/6 * SJL
|
abnormal CD8-positive, alpha beta T cell morphology |
J:125259
|
Tg(Tcra2C,Tcrb2C)1Dlo/?
involves: C57L * DBA/2 * SJL
|
abnormal dermis papillary layer morphology |
J:95380
|
|
abnormal memory T cell physiology |
J:95380
|
|
decreased lymphocyte cell number |
J:95380
|
|
decreased thymocyte number |
J:95380
|
|
increased CD4-positive, alpha-beta T cell number |
J:95380
|
|
seborrheic dermatitis |
J:95380
|
|
thick epidermis |
J:95380
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal T-helper 1 cell number |
J:189919
|
|
decreased interferon-gamma secretion |
J:189919
|
|
decreased interleukin-2 secretion |
J:189919
|
|
decreased interleukin-10 secretion |
J:189919
|
|
decreased T cell proliferation |
J:189919
|
|
decreased T-helper 2 cell number |
J:189919
|
|
decreased T-helper 17 cell number |
J:189919
|
|
increased interferon-gamma secretion |
J:189919
|
|
increased interleukin-6 secretion |
J:189919
|
|
increased interleukin-17 secretion |
J:189919
|
|
increased T cell apoptosis |
J:189919
|
|
increased T cell proliferation |
J:189919
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:83278
|
|
abnormal cytokine secretion |
J:83278
|
|
abnormal eye morphology |
J:83278
|
|
abnormal optic nerve morphology |
J:83278
|
|
axon degeneration |
J:83278
|
|
blepharitis |
J:83278
|
|
CNS inflammation |
J:83278
|
|
demyelination |
J:83278
|
|
edema |
J:83278
|
|
eyelid edema |
J:83278
|
|
increased cell proliferation |
J:83278
|
|
increased susceptibility to autoimmune disorder |
J:83278
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:83278
|
|
increased susceptibility to induced morbidity/mortality |
J:83278
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/?
involves: C57BL/6 * CD-1
|
decreased interleukin-17 secretion |
J:125296
|
Tg(Tcra5CC7,Tcrb5CC7)IWep/0
involves: C57BL/6
|
abnormal T cell activation |
J:73608
|
Tg(Tcra51-11.5,Tcrb51-11.5)AR206Ayr/0
involves: C57BL/6 * DBA/2
|
abnormal positive T cell selection |
J:125548
|
Tg(Tcra,Tcrb)3Ayr/0
involves: C57BL/6 * DBA/2
|
abnormal lymphocyte anergy |
J:80775
|
|
abnormal positive T cell selection |
J:125548
|
|
decreased T cell proliferation |
J:80775
|
Tg(Tcra,Tcrb)24Efro/0
D1.Cg-Tg(Tcra,Tcrb)24Efro
|
abnormal cytokine secretion |
J:104243
|
|
abnormal T cell differentiation |
J:104243
|
|
autoimmune response |
J:104243
|
|
decreased T cell proliferation |
J:104243
|
|
increased autoantibody level |
J:104243
|
|
increased memory T cell number |
J:104243
|
|
increased susceptibility to autoimmune disorder |
J:104243
|
|
increased T cell proliferation |
J:104243
|
Tg(Tcra,Tcrb)HRCAll/0
B6.Cg-Tg(Tcra,Tcrb)HRCAll
|
abnormal T cell subpopulation ratio |
J:131347
|
|
decreased CD4-positive, alpha-beta T cell number |
J:131347
|
|
decreased cytotoxic T cell cytolysis |
J:131347
|
|
decreased interferon-gamma secretion |
J:131347
|
|
increased CD8-positive, alpha-beta T cell number |
J:131347
|
Tg(Tcra,Tcrb)HRVAll/0
B6.Cg-Tg(Tcra,Tcrb)HRVAll
|
abnormal T cell subpopulation ratio |
J:131347
|
|
decreased CD4-positive, alpha-beta T cell number |
J:131347
|
|
increased CD8-positive, alpha-beta T cell number |
J:131347
|
Tg(Tcra,Tcrb)HRVAll/0
Tg(TRAMP)8247Ng/0
B6.Cg-Tg(TRAMP)8247Ng Tg(Tcra,Tcrb)HRVAll
|
increased prostate gland tumor incidence |
J:131347
|
|
increased tumor incidence |
J:131347
|
|
premature death |
J:131347
|
Tg(TcraAI4)1Dvs/0
Tg(TcrbAI4)1Dvs/0
NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs
|
abnormal CD4-positive, alpha beta T cell morphology |
J:93553
|
|
abnormal CD8-positive, alpha beta T cell morphology |
J:94192
|
|
abnormal cytotoxic T cell physiology |
J:94192
|
|
increased susceptibility to autoimmune diabetes |
J:94192
|
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: C57BL/6 * NOD * SJL
|
decreased dendritic cell number |
J:137009
|
|
normal
digestive/alimentary phenotype |
J:135214
|
|
normal
immune system phenotype |
J:135214
|
|
insulitis |
J:137009
|
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi
|
decreased susceptibility to autoimmune diabetes |
J:87251
|
|
increased activated T cell number |
J:52940
|
|
insulitis |
J:52940
|
Tg(TcraCl1,TcrbCl1)1Shrm/0
B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm
|
abnormal fertility/fecundity |
J:106230
|
|
abnormal T cell subpopulation ratio |
J:97745
|
|
increased tumor incidence |
J:106230
|
|
weakness |
J:106230
|
Tg(TcraCl4,TcrbCl4)1Shrm/?
B10.Cg-H2d Tg(TcraCl4,TcrbCl4)1Shrm
|
abnormal CD8-positive, alpha-beta T cell differentiation |
J:99756
|
|
abnormal T cell subpopulation ratio |
J:99756
|
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6 * DBA/2J
|
abnormal cytotoxic T cell physiology |
J:66565
|
|
abnormal T cell differentiation |
J:97610
|
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: C57BL/6J * C57L/J * DBA/2J
|
abnormal double-negative T cell morphology |
J:79738
|
|
abnormal T cell differentiation |
J:79738,
J:90776
|
|
decreased thymocyte number |
J:79738
|
|
thymus hypoplasia |
J:79738
|
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
Themistm1Gasc/Themistm1Gasc
involves: 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal negative T cell selection |
J:151074
|
|
abnormal positive T cell selection |
J:151074
|
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
Themistm1Lov/Themistm1Lov
involves: 129 * C57BL/6 * DBA/2
|
abnormal negative T cell selection |
J:151075
|
|
abnormal positive T cell selection |
J:151075
|
|
decreased single-positive T cell number |
J:151075
|
|
increased double-positive T cell number |
J:151075
|
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
Tnfrsf25tm1Mjo/Tnfrsf25tm1Mjo
involves: 129P2/OlaHsd * C57BL/6J * DBA/2J
|
abnormal negative T cell selection |
J:84536
|
|
abnormal thymus morphology |
J:84536
|
|
increased thymocyte number |
J:84536
|
Tg(TcrAND)53Hed/?
involves: A/WySnSg * C57BL/6 * C57BL/10SnSg * SJL
|
abnormal positive T cell selection |
J:85777
|
|
abnormal T cell differentiation |
J:85777
|
|
abnormal T cell proliferation |
J:85777
|
|
abnormal T cell subpopulation ratio |
J:85777
|
|
abnormal thymocyte activation |
J:85777
|
|
decreased CD8-positive, alpha-beta T cell number |
J:85777
|
|
decreased double-positive T cell number |
J:85777
|
|
increased CD4-positive, alpha-beta T cell number |
J:85777
|
Tg(TcrAND)53Hed/?
involves: C57BL/6 * SJL
|
abnormal lymph node cell ratio |
J:124701
|
|
increased CD4-positive, alpha-beta T cell number |
J:124701
|
Tg(TcrAND)53Hed/?
Themistm1Gasc/Themistm1Gasc
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:151074
|
|
decreased CD4-positive, alpha-beta T cell number |
J:151074
|
|
decreased CD8-positive, alpha-beta T cell number |
J:151074
|
|
increased double-positive T cell number |
J:151074
|
Tg(TcrAND)53Hed/?
Themistm1Lov/Themistm1Lov
involves: 129 * C57BL/6 * SJL
|
abnormal positive T cell selection |
J:151075
|
|
decreased single-positive T cell number |
J:151075
|
|
increased double-positive T cell number |
J:151075
|
Tg(TcrAND)53Hed/?
Zbtb7btm1.1Rbo/Zbtb7btm1.1Rbo
involves: C57BL/6 * SJL
|
abnormal T cell differentiation |
J:141145
|
Tg(TcraR28,TcrbR28)KRNDim/0
involves: C57BL/6 * NOD * SJL
|
abnormal intervertebral disk morphology |
J:36815
|
|
abnormal lymphocyte cell number |
J:36815
|
|
abnormal macrophage chemotaxis |
J:36815
|
|
abnormal metatarsal bone morphology |
J:36815
|
|
abnormal phalanx morphology |
J:36815
|
|
abnormal T cell activation |
J:36815
|
|
abnormal T cell anergy |
J:36815
|
|
abnormal T cell clonal deletion |
J:36815
|
|
abnormal T cell proliferation |
J:36815
|
|
chronic joint inflammation |
J:36815
|
|
clinodactyly |
J:36815
|
|
decreased CD4-positive, alpha-beta T cell number |
J:36815
|
|
decreased CD8-positive, alpha-beta T cell number |
J:36815
|
|
decreased joint mobility |
J:36815
|
|
enlarged spleen |
J:36815
|
|
glomerulonephritis |
J:36815
|
|
impaired neutrophil recruitment |
J:36815
|
|
increased B cell number |
J:36815
|
|
increased IgG1 level |
J:36815
|
|
kidney inflammation |
J:36815
|
|
renal glomerular immunoglobulin deposits |
J:36815
|
|
rheumatoid arthritis |
J:36815
|
Tg(TcraTcrb)8Rest/?
C57BL/6-Tg(TcraTcrb)8Rest
|
abnormal CD8-positive, alpha-beta cytotoxic T cell morphology |
J:85058
|
|
abnormal cytotoxic T cell physiology |
J:85058
|
|
abnormal tumor susceptibility |
J:85058
|
|
increased interferon-gamma secretion |
J:85058
|
Tg(TcraTcrb)425Cbn/0
involves: BALB/c * C57BL/6
|
abnormal positive T cell selection |
J:125548
|
Tg(TcraTcrb)425Cbn/?
involves: BALB/c * C57BL/6
|
abnormal positive T cell selection |
J:87876
|
|
increased CD4-positive, alpha-beta T cell number |
J:87876
|
Tg(TcraTcrb)425Cbn/0
involves: C57BL/6
|
abnormal cytokine level |
J:112600
|
Tg(TcraTcrb)425Cbn/0
Trim30atm1Yjk/Trim30atm1Yjk
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
increased T cell proliferation |
J:215171
|
Tg(TcraTcrb)425Cbn/0
Trip10tm1.1Geha/Trip10tm1.1Geha
B6.Cg-Trip10tm1.1Geha Tg(TcraTcrb)425Cbn
|
abnormal effector T cell morphology |
J:164363
|
|
decreased CD4-positive, alpha-beta T cell number |
J:164363
|
|
normal
immune system phenotype |
J:164363
|
Tg(TcraTcrb)1100Mjb/?
either: C57BL/6 or (involves: C57BL/6 * SJL)
|
increased tumor latency |
J:134776
|
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6
|
abnormal CD8-positive, alpha beta T cell morphology |
J:92867
|
|
abnormal cytotoxic T cell physiology |
J:92867,
J:133645
|
|
abnormal positive T cell selection |
J:92867,
J:133645
|
|
abnormal T cell clonal deletion |
J:92867
|
|
abnormal T cell subpopulation ratio |
J:92867,
J:133645
|
|
decreased CD4-positive, alpha-beta T cell number |
J:133645
|
|
increased CD8-positive, alpha-beta T cell number |
J:92867,
J:133645
|
|
increased T cell proliferation |
J:92867
|
Tg(TcraTcrb)1100Mjb/?
involves: C57BL/6 * MRL/Mp
|
increased hepatocyte apoptosis |
J:72817
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:72817
|
|
liver inflammation |
J:72817
|
|
pale liver |
J:72817
|
Tg(TcraTcrb)1100Mjb/?
Themistm1Gasc/Themistm1Gasc
involves: 129S6/SvEvTac * C57BL/6
|
abnormal positive T cell selection |
J:151074
|
|
decreased CD8-positive, alpha-beta T cell number |
J:151074
|
|
increased double-positive T cell number |
J:151074
|
Tg(TcraTcrbNY4.1)1Pesa/0
NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa
|
increased susceptibility to autoimmune diabetes |
J:108768
|
|
insulitis |
J:108768
|
Tg(TcraTcrbNY8.3)1Pesa/?
involves: C57BL/6 * NOD * SJL
|
increased circulating glucose level |
J:44202
|
|
pancreas inflammation |
J:44202
|
Tg(TcraY1,TcrbY1)416Tev/0
involves: C57BL/6J * DBA/2J
|
abnormal immune tolerance |
J:84288
|
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6
|
abnormal CD4-positive, alpha beta T cell morphology |
J:73608
|
|
abnormal interleukin secretion |
J:73608
|
|
abnormal T cell activation |
J:73608
|
|
increased T cell proliferation |
J:73608
|
Tg(TcrHEL3A9)1Mmd/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal double-positive T cell morphology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
abnormal thymus cell ratio |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
Tg(TcrHEL3A9)1Mmd/0
Tg(TLK2mHEL)2Ccg/0
involves: C57BL/6 * C57BL/10 * C57BR/cd
|
abnormal CD4-positive, alpha beta T cell morphology |
J:78309
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:78309
|
|
abnormal T cell activation |
J:78309
|
|
abnormal T cell proliferation |
J:78309
|
|
decreased CD4-positive, alpha-beta T cell number |
J:78309
|
|
decreased double-positive T cell number |
J:78309
|
|
thyroid gland inflammation |
J:78309
|
Tg(TcrLCMV)1Aox/?
C57BL/6-Tg(TcrLCMV)1Aox
|
abnormal cytotoxic T cell physiology |
J:92228
|
|
decreased CD8-positive, alpha-beta T cell number |
J:92228
|
|
decreased double-positive T cell number |
J:92228
|
|
increased CD4-positive, alpha-beta T cell number |
J:92228
|
|
increased double-negative T cell number |
J:92228
|
|
increased IgG level |
J:92228
|
Tg(TcrLCMV)2Aox/?
C57BL/6-Tg(TcrLCMV)2Aox
|
abnormal cytotoxic T cell physiology |
J:92228
|
|
decreased CD8-positive, alpha-beta T cell number |
J:92228
|
|
decreased double-positive T cell number |
J:92228
|
|
increased CD4-positive, alpha-beta T cell number |
J:92228
|
|
increased double-negative T cell number |
J:92228
|
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2
|
decreased CD8-positive, alpha-beta T cell number |
J:77696
|
|
decreased cytotoxic T cell cytolysis |
J:77696
|
|
decreased double-positive T cell number |
J:77696
|
|
decreased T cell proliferation |
J:77696
|
|
thymus hypoplasia |
J:77696
|
Tg(TcrLCMV)327Sdz/?
involves: C57BL/6 * DBA/2J
|
abnormal T cell differentiation |
J:97610
|
|
decreased CD4-positive, alpha-beta T cell number |
J:97610
|
Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz
NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs
|
autoimmune response |
J:71050
|
Tgfb1tm3.1Flv/Tgfb1tm3.1Flv
Tg(Cd4-cre)1Cwi/0
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129 * C57BL/6 * DBA/2 * NOD * SJL
|
increased regulatory T cell number |
J:196160
|
|
increased susceptibility to autoimmune diabetes |
J:196160
|
|
increased T-helper 1 cell number |
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Cd4-cre)1Cwi/0
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129 * C57BL/6 * DBA/2 * NOD * SJL
|
abnormal abdominal lymph node morphology |
J:196160
|
|
abnormal immune serum protein physiology |
J:196160
|
|
abnormal immune system morphology |
J:196160
|
|
abnormal immune system organ morphology |
J:196160
|
|
abnormal immune system physiology |
J:196160
|
|
abnormal interleukin secretion |
J:196160
|
|
abnormal spleen morphology |
J:196160
|
|
decreased interleukin-9 secretion |
J:196160
|
|
decreased interleukin-17 secretion |
J:196160
|
|
decreased regulatory T cell number |
J:196160
|
|
normal
immune system phenotype |
J:196160
|
|
increased interferon-gamma secretion |
J:196160
|
|
increased interleukin-2 secretion |
J:196160
|
|
increased interleukin-21 secretion |
J:196160
|
|
increased regulatory T cell number |
J:196160
|
|
increased susceptibility to autoimmune diabetes |
J:196160
|
|
normal
mortality/aging |
J:196160
|
|
pancreas inflammation |
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tg(Foxp3-EGFP/cre)1cJbs/0
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129S6/SvEvTac * C57BL/6 * NOD * SJL
|
normal
immune system phenotype |
J:196160
|
|
increased regulatory T cell number |
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
Tnfrsf4tm2(cre)Nik/Tnfrsf4+
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
involves: 129 * C57BL/6 * NOD * SJL
|
normal
immune system phenotype |
J:196160
|
|
increased susceptibility to autoimmune diabetes |
J:196160
|
Tigittm1Sdl/Tigittm1Sdl
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: C57BL/6
|
decreased interleukin-10 secretion |
J:168902
|
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:168902
|
Vsirtm1Lex/Vsirtm1Lex
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
involves: 129S5/SvEvBrd * C57BL/6
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:222944
|
Xcl1tm1Rakr/Xcl1tm1Rakr
Tg(TcraTcrb)1100Mjb/0
involves: 129/Sv * C57BL/6
|
abnormal CD8-positive, alpha-beta T cell physiology |
J:155297
|
|
decreased cytotoxic T cell cytolysis |
J:155297
|
|
decreased interferon-gamma secretion |
J:155297
|
|
decreased T cell number |
J:155297
|
Zap70m1Saka/Zap70m1Saka
Tg(DO11.10)10Dlo/0
involves: BALB/c * C3H * C57BL/6
|
decreased T cell number |
J:86607
|
|
decreased T cell proliferation |
J:86607
|
Zap70m1Saka/Zap70m1Saka
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: BALB/c * C57BL/6J * DBA/2J
|
abnormal positive T cell selection |
J:86607
|
|
autoimmune arthritis |
J:86607
|
Zap70tm1.1Mmal/Zap70tm1.1Mmal
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J
|
normal
immune system phenotype |
J:71099
|
Zap70tm1.1Mmal/Zap70tm1.1Mmal
Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2
|
abnormal cytokine secretion |
J:71099
|
|
abnormal T cell proliferation |
J:71099
|
|
normal
immune system phenotype |
J:71099
|
Zap70tm2.1Mmal/Zap70tm2.1Mmal
Tg(TcraH-Y,TcrbH-Y)71Vbo/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6J * DBA/2J
|
abnormal lymph node cell ratio |
J:71099
|
|
abnormal T cell morphology |
J:71099
|
|
abnormal thymus cell ratio |
J:71099
|
|
normal
immune system phenotype |
J:71099
|
Zap70tm2.1Mmal/Zap70tm2.1Mmal
Tg(TcrLCMV)327Sdz/0
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2
|
abnormal T cell morphology |
J:71099
|
|
normal
immune system phenotype |
J:71099
|
Zap70tm2.1Weis/Zap70tm2.1Weis
Tg(DO11.10)10Dlo/?
involves: 129S4/SvJae * BALB/c * C3H * C57BL/6
|
abnormal positive T cell selection |
J:154166
|
Zap70tm2.1Weis/Zap70tm2.1Weis
Tg(TcraH-Y,TcrbH-Y)71Vbo/?
involves: 129S4/SvJae * C57BL/6J * DBA/2J
|
abnormal positive T cell selection |
J:154166
|
|
abnormal T cell clonal deletion |
J:154166
|
Analysis Tools
Excel File